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Abstract: Infections caused by Candida species have been increasing in the last decades and can
result in local or systemic infections, with high morbidity and mortality. After Candida albicans,
Candida glabrata is one of the most prevalent pathogenic fungi in humans. In addition to the high
antifungal drugs resistance and inability to form hyphae or secret hydrolases, C. glabrata retain many
virulence factors that contribute to its extreme aggressiveness and result in a low therapeutic response
and serious recurrent candidiasis, particularly biofilm formation ability. For their extraordinary
organization, especially regarding the complex structure of the matrix, biofilms are very resistant to
antifungal treatments. Thus, new approaches to the treatment of C. glabrata’s biofilms are emerging.
In this article, the knowledge available on C. glabrata’s resistance will be highlighted, with a special
focus on biofilms, as well as new therapeutic alternatives to control them.
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1. Introduction
1.1. Biology of Candida glabrata
Historically, Candida glabrata strains were originally classified in the genus Torulopsis due to its
lack of filaments forms formation. However, in 1978 it was determined that the ability to form hyphae
and/or pseudohyphae was not a reliable distinguishing factor of members of genus Candida species,
and it was proposed that T. glabrata should be classified in the genus Candida, due to its human
pathogenicity [1]. In fact, in contrast to other Candida species, C. glabrata is not polymorphic, growing
only as blastoconidia and regarding the genetic aspects of Candida species, a critical distinguishing
characteristic of this species is its haploid genome, in opposition to the diploid genome of
Candida albicans and other Candida species. It should be highlighted that C. glabrata cells (1–4 µm)
are noticeably smaller than C. albicans (4–6 µm), Candida tropicalis (4–8 µm), and other Candida
species blastoconidia [2] (Figure 1). In Sabouraud dextrose agar culture medium, C. glabrata strains
forms glistening, smooth, and cream-coloured colonies, which are relatively indistinguishable from
those of other Candida species except for their relative size (Figure 1), which can be quite small [3].
On CHROMagarTM Candida (CHROMagar, Paris, France), a differential agar medium, it is possible to
distinguish a number of different Candida species by colour; as a result of distinct biochemical reactions,
C. glabrata colonies appear white, pink to purple (Figure 1), in contrast to C. albicans colonies which
are blue-green. Concerning the biochemical reactions of Candida species, C. glabrata ferments and
assimilates only glucose and trehalose, contrary to C. albicans, which ferments and/or assimilates a
high number of sugars excluding sucrose [4,5]. Whereas C. albicans, Candida parapsilosis, and C. tropicalis
are moderately closely related species of the CUG clade, which share a unique codon exchange from
leucine to serine, C. glabrata is actually a “misnomer”, for it is really much more closely related to the
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Saccharomyces cerevisiae than to C. albicans [6,7]. As mentioned, oppositely to the other Candida species,
but equally to its cousin S. cerevisiae, C. glabrata is strictly haploid and typically grows only in the yeast
form [8].
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Figure 1. Candida glabrata cells: (A) microscopy structure; (B) on CHROMagarTM Candida; (C) on 
Sabouraud dextrose agar (adapted from [4]). The scale corresponds to 50 µm with a magnification of 
200×. 
1.2. Epidemiology and Virulence Factors of Candida glabrata 
For many years C. glabrata was considered a relatively non-pathogenic saprophyte of the normal 
flora of healthy individuals and certainly not readily associated with serious infections in humans. 
However, following the widespread and increased use of immunosuppressive therapy together with 
broad–spectrum antibiotic and antifungal therapies, the frequency of mucosal and systemic 
infections caused by C. glabrata has been growing significantly [9]. In fact, whilst mycological studies 
have been shown that C. albicans represents approximately 80% of the clinical isolates, in the last few 
decades, the number of candidiasis due to non-Candida albicans Candida (NCAC) species has 
meaningfully raised, namely in regard to C. glabrata strains [1,10,11]. Some studies suggest that 
fungemia has been associated with NCAC species [11–13]. The incidence of C. glabrata is higher in 
adults than in children, and is lower in neonates [14,15]. In the European Confederation of Medical 
Mycology survey, the frequency rates of candidiasis attributed to C. glabrata were around 14% [16] 
and 15% of all Candida-related systemic bloodstream infections [17,18]. This is extremely important 
since, compared to other Candida species infections, the mortality rate associated with C. glabrata is 
the highest [19]. 
Subsequently to the introduction of the highly active antiretroviral therapy, a reduction in the 
percentage of oropharyngeal infections, the colonisation by Candida species, and a decline in the 
frequency of fluconazole resistance in patients with HIV infection have been recorded [20]. However, 
Candida species are still the most frequent cause of systemic mycosis in our time [21,22]. During 1995–
1996 and 1997–1998, a national programme of surveillance of bloodstream infections in the USA [23], 
and the SENTRY international programme of surveillance of bloodstream infections in the USA, 
Canada, and South America [24], showed the rising importance of NCAC, which accounted for 
between 44% and 48% of cases of fungaemia. Among NCAC, C. glabrata clearly stood out, with an 
increased prevalence observed through the study period in all three geographical regions, becoming 
the second most frequent species after C. albicans in the USA and Canada [23,24] and with a mortality 
rate associated with bloodstream infections of 49% in a retrospective series of 139 cases [25]. In the 
European SENTRY programme C. glabrata was the third most common NCAC, after C. parapsilosis 
[26]. In considering the SENTRY programme of USA from 1997–1999, NCAC were usually more 
susceptible to fluconazole, but continued surveillance is needed to confirm this tendency, as it is 
known that this may be not accurate in present days, mostly for C. glabrata and Candida krusei, which 
are known to be intrinsically resistant to fluconazole [23,24,26–31]. 
Until recently, few studies had evaluated independent risk factors associated with nosocomial 
C. glabrata acquisition and subsequent infection. Little is known about the hospital reservoirs of C. 
glabrata, but with C. albicans, probable sources include a complex interaction of environmental and 
human reservoirs [32]. Vasquez and colleagues [33] revealed that patients with a new acquisition of 
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1.2. Epide iology and Virulence Factors of Candida glabrata
For any years C. glabrata as considered a relatively non-pathogenic saprophyte of the nor al
flora of healthy individuals and certainly not readily associated ith serious infections in hu ans.
o ever, follo ing the idespread and increased use of i unosuppressive therapy together ith
broad–spectru antibiotic and antifungal therapies, the frequency of mucosal and systemic infections
caused by C. glabrata has been growing significantly [9]. In fact, whilst mycological studies have been
shown that C. albicans represents approximately 80% of the clinical isolates, in the last few decades,
the number of candidiasis due to non-Candida albicans Candida (NCAC) species has meaningfully
raised, namely in regard to C. glabrata strains [1,10,11]. Some studies suggest that fungemia has
been associated with NCAC species [11–13]. The incidence of C. glabrata is higher in adults than
in children, and is lower in neonates [14,15]. In the European Confederation of Medical Mycology
survey, the frequency rates of candidiasis attributed to C. glabrata were around 14% [16] and 15% of all
Candida-related systemic bloodstream infections [17,18]. This is extremely important since, compared
to other Candida species infections, the mortality rate associated with C. glabrata is the highest [19].
Subsequently to the introduction of the highly active antiretroviral therapy, a reduction in the
percentage of oropharyngeal infections, the colonisation by Candida species, and a decline in the
frequency of fluconazole resistance in patients with HIV infection have been recorded [20]. However,
Candida species are still the most frequent cause of systemic mycosis in our time [21,22]. During
1995–1996 and 1997–1998, a national programme of surveillance of bloodstream infections in the
USA [23], and the SENTRY international programme of surveillance of bloodstream infections in the
USA, Canada, and South America [24], showed the rising importance of NCAC, which accounted for
between 44% and 48% of cases of fungaemia. Among NCAC, C. glabrata clearly stood out, with an
increased prevalence observed through the study period in all three geographical regions, becoming
the second most frequent species after C. albicans in the USA and Canada [23,24] and with a mortality
rate associated with bloodstream infections of 49% in a retrospective series of 139 cases [25]. In the
European SENTRY programme C. glabrata was the third most common NCAC, after C. parapsilosis [26].
In considering the SENTRY programme of USA from 1997–1999, NCAC were usually more susceptible
to fluconazole, but continued surveillance is needed to confirm this tendency, as it is known that this
may be not accurate in present days, mostly for C. glabrata and Candida krusei, which are known to be
intrinsically resistant to fluconazole [23,24,26–31].
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Until recently, few studies had evaluated independent risk factors associated with nosocomial
C. glabrata acquisition and subsequent infection. Little is known about the hospital reservoirs of
C. glabrata, but with C. albicans, probable sources include a complex interaction of environmental and
human reservoirs [32]. Vasquez and colleagues [33] revealed that patients with a new acquisition of
C. glabrata had extended and repeated hospitalizations prior to antifungal use compared to patients
with no Candida species exposition. Candida glabrata has been also often isolated from patients with
oral candidiasis, alone or coupled with C. albicans clinical isolates [4,34] and thus, has been related
to recurrent systemic infections [35,36]. The propensity of C. glabrata for dissemination and the high
mortality associated could be related to the virulence factors that this species exhibits, namely the
elevated rates of resistance to the traditional antifungals.
The relatively nonpathogenic nature of C. glabrata in animal models [37,38] suggests that it has
only few virulence attributes. However, the high mortality rate and the rapidity of the spread of
disease would suggest the contrary [1]. In fact, in opposition to its inability to form hyphae and/or
pseudohyphae and secret proteases, C. glabrata retain many virulence factors such as the capacity to
secrete phospholipases, lipases, and haemolysins that contribute towards an extreme aggressiveness
resulting in a low therapeutic response and serious recurrent candidiasis [10,39]. However, its most
worrying virulence factor is its strong capability to form biofilms [10,40,41]. Biofilms are known
as surface-associated communities of microorganisms embedded in an extracellular matrix [42,43],
which confer significant antifungal therapy and host immune responses [4,10,41]. Candida glabrata
clinical isolates have the ability to form a compact biofilm structure in different multilayers [40,41],
with proteins, carbohydrates (e.g., β-1,3 glucans), and ergosterol in their matrixes [40,41,44]. The first
step of C. glabrata biofilm development is adhesion and/or colonisation of yeast cells to an abiotic
or/and biotic surface [4,10]. Adhesion is an extremely important step, not only in the biofilm formation,
but also in the infections processes, and the extent of adhesion is dependent on C. glabrata cells’
characteristics, and host and/or abiotic surface properties, such as cell-surface hydrophobicity and
cell wall composition [4,45]. The Candida glabrata cell wall is the site for physicochemical interactions
between the microorganism and the surfaces, leading to its adherence. Despite the lack of studies
concerning this issue, it is assumed that the cell surface of C. glabrata cells reportedly exhibit a degree
of hydrophobicity comparable with C. albicans [46]. Interestingly, however, while the hydrophobicity
of C. albicans was extremely sensitive to specific growth conditions, numerous isolates of C. glabrata
were relatively insensitive to those same growth conditions [47]. Similar to C. albicans, C. glabrata
adhesion phenomenon is mediated by epithelial adhesins (Epa) that have a comparable structure to
the Als proteins [48]. The family of EPA genes are composed of 17–23 genes depending on the strain,
however, EPA1, EPA6, and EPA7 are the most important adhesins [49]. Deletion of the EPA1 gene
reduces C. glabrata adherence in vitro to host epithelial cells [50] and the adherence of this adhesin was
inhibited in the presence of lactose [51]. In addition, usually C. glabrata strains are unable to express
EPA6 in vitro, however, it is expressed during urinary infection, due to low levels of nicotinic acid [51].
Groot et al. [52] identified another family of adhesins involved in the first stage of C. glabrata biofilm
development, namely Awp adhesins. Initially, four Awp adhesins (Awp1–4) were identified using
liquid chromatography tandem mass spectrometry [52], and a subsequent study revealed the gene
expression profile of the seven Awp adhesins (Awp1–7) [53]. Initial attachment of C. glabrata cells is
followed by cell division, and this proliferation leads to the formation of a basal layer of anchoring
microcolonies, with subsequent biofilm maturation [4,44]. Biofilm conditions and high cell density
are adhesion inducers, activating EPA6, whereas EPA1 is triggered typically in the lag phase and the
C. glabrata biofilm maturation is characterized by the production of the extracellular matrix [4,54].
A study using isolated mutant strains allowed the identification of four other genes involved in biofilm
formation: silent information regulator (SIR4), telomere-binding (RIF1), EPA6, and serine-threonine
protein kinase, YAK1.
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2. General Mechanisms of Antifungal Drug Resistance
Clinical resistance is the result of a failure in the infection treatment [55]. Regarding susceptibility
or resistance, Candida is defined as susceptible or resistant by the level of antifungal drug activity
associated with a high likelihood of therapeutic success or therapeutic failure, correspondingly.
There has been an epidemiological change from C. albicans to NCAC species, with C. glabrata and
C. krusei emerging as important and potentially antifungal resistant causes of candidaemia [56]. It is
important to mention that C. glabrata has been frequently reported as exhibiting variable karyotypes
between isolates [57–64], and several studies with Candida species have demonstrated that these
karyotypes are relatively stable, suggesting that the karyotype of virulent species is more stable than
virulent ones [65]. The major karyotypic differences between C. glabrata strains are linked to a small
number of chromosomal translocations. Along with variation in the subtelomeric EPA genes, the
other genomic rearrangements are copy number variations in tandem gene repeats, encoding putative,
or known cell wall proteins [58].
Bader et al. [66] analysed the derivates in C. glabrata strains’ genome, which were shown to
be indistinguishable by multi locus sequence typing, but dissimilar phenotypic groups that were
linked with specific karyotypic changes were also spotted. Chromosomal aberrations and functional
adaptations can occur during infection and under antimicrobial therapy, but also under laboratory
conditions deprived of extreme selective pressures, and can significantly affect phenotypic properties
(e.g., the cell wall carbohydrate composition and quantitative changes in adhesion genes expression),
being noticed slightly less than subtelomeric genes loss or differences in the number of macrosatellite
repeats within adhesion genes. Another study also revealed that chromatin alterations could happen as
essential strategies of survival, which would simplify a reprogramming of cellular energy metabolism
in macrophage-internalized C. glabrata cells, and provide protection against DNA damage [67]. Thus,
similar to all Candida species, C. glabrata have the competence to respond to environmental alterations,
allowing them to adapt to the presence of antifungal agents, thereby providing protection against
antimicrobial therapies [68].
Cell wall fluctuations, but mostly its immunoevasion and intracellular persistence, may be
the crucial factors in the great ability of C. glabrata to persist in the course of multiple antifungal
treatments and to develop multidrug resistance [69,70]. Consequently, different mechanisms of
resistance vary among drugs, typically because of the mode of action of each class of antifungal.
There are, presently, three main antifungal classes: azoles, polyenes and echinocandins. The azoles
are known to have fungistatic activity, targeting the ergosterol biosynthetic pathway, by binding to
the Cyp51 family of cytochrome P450—the 14-α sterol demethylases that are encoded by ERG11.
They are responsible for the lack in the capacity to build and renew sterols in the cellular membranes,
changing membrane fluidity and function of vital processes such as signalling, transport, exocytosis,
and endocytosis [10]. Fluconazole, voriconazole, itraconazole, clotrimazole, and posaconazole are
main examples. The polyenes (e.g., amphotericin B, nystatin) and echinocandins (e.g., micafungin,
caspofungin, anidulafungin) are fungicidal drugs. The first ones bind to the ergosterol of the fungal
cell membrane establishing transmembrane aggregates pores, which causes membrane depolarization
which subsequently increases its permeability to monovalent protons and cations. This allows the
passage of intracellular molecules to the external environment, initiating an osmotic imbalance,
and finally cell death [71–73]. Echinocandins interfere with the fungal cell wall synthesis through a
non-competitive inhibition of β-1,3-glucan synthesis [74], which results in the weakening of the cell
wall, breakdown of cellular integrity and, finally, cell lysis [75].
2.1. Azole’s Resistance
During the past few decades there was a remarkable increase in mucosal infections caused by
Candida species due to the increase of immunosuppressive diseases (e.g., cancer, AIDS), which was
associated with an extraordinary emergence of resistance to azoles [76]. In the early 1990s, fluconazole
became the first choice drug in the treatment and prophylaxis of oro-oesophageal candidiasis, and
J. Fungi 2017, 3, 11 5 of 30
resistance was subsequently described in up to 41% of the patients in the following years [77–79]. Also,
an increase was observed in the cases of fungaemia caused by NCAC species, specially C. glabrata and
C. krusei [19,80–82]. As recognized, C. glabrata grows only as a yeast form in vivo and its adhesion is
relatively weak [83–85]. Thus, it is believed that the increase of C. glabrata infections is due to that same
inherent low susceptibility to azoles [86] and that the acquired resistance is a result of rare mutations
that are selected by drug pressure [87]. Studies appear to conclude that the azole resistance develops
gradually as a consequence of successive adjustments due to the continuous pressure exerted by the
drug [87–89]. The acquired resistance of C. glabrata to azole drugs is linked to several mechanisms, but
the most common is the induction of efflux pumps, encoded by the ABC-transporter genes (CDR1 and
CDR2, SNQ2) or to MDR belonging to the major facilitator superfamily (MFS) that lead to decreased
drug concentration [90]. In C. glabrata, the transcription factor Pdr1 is involved in resistance to azoles
through upregulation of CDR1, CDR2, and SNQ2 [91]. The mitochondrial dysfunction associated with
the development of the “petite mutants”, which have mitochondrial DNA deficiency and upregulate
the ABC transporter genes, highly amplifying resistance to azoles, leading to a drastic improvement of
fitness in C. glabrata. These mutants upregulate ABC transporter genes, displaying enlarged resistance
to azole drugs [92]. A number of ABC transporters, including Cdr1, Pdh1 (also known as CDR2), Yor1,
and Snq2, contribute to xenobiotic drug efflux. The transcription factor Pdr1 is the main regulator of
ABC transporter gene expression and the key component of Pleiotropic Drug Resistance (PDR) [93,94].
In C. glabrata, Pdr1 forms a heterodimer with Stb5 in S. cerevisiae and transcriptional analysis pointed
out a shared region among the homologues of these two genes, PDR1 and STB5, and many of the genes
upregulated by overexpression of PDR1 were upregulated by the deletion of STB5. Accordingly, the
PDR1 overexpression and STB5 deletion are correlated [95,96]. It was found that the overexpression of
STB5 in C. glabrata represses azole resistance, while its deletion produces a minor intensification in
resistance. Expression analysis assays recognized that STB5 shares many transcriptional targets with
PDR1 but, unlike the second, it is a negative regulator of pleiotropic drug resistance (including the
ABC transporter genes CDR1, PDH1, and YOR1) [91,96]. A study by Farahyar et al. [97] demonstrated
that CDR1 and CDR2 genes are expectedly upregulated in azole-resistant isolates (≥2-fold) and that,
fatty acid activator 1 (FAA1) gene presented a ≥2-fold expression in resistant isolates, when compared
to the susceptible isolates and the reference strain. The work also revealed that not only the ABC
transporter genes, but also small hydrophobic compounds and lipid metabolism may have a huge
responsibility in azole drug resistance of C. glabrata [97]. A study of Ferrari and colleagues [91]
involving transcription profiling with microarrays showed that more than 385 genes are differentially
regulated by a selected number of the gain-of-function mutations (GOFs) expressed in the same genetic
background, with a minimal overlap in co-regulated genes. CDR1 and PUP1 (for PDR1 upregulated
and encoding a mitochondrial protein) were generally upregulated by all tested GOFs. While both
genes mediated azole resistance, their deletions resulted in a decline in virulence and a decrease in
tissue load. Their individual overexpression was shown to partially restore phenotypes obtained in
clinical isolates [91]. Kaur and colleagues [98] made a screening of a library of 9216 random insertion
mutants, and identified a set of 27 genes, which upon mutation, conferred alterations in fluconazole
susceptibility in C. glabrata. These genes included ABC transporters (PDR5 and PDR16), genes involved
in retrograde signalling from mitochondria to nucleus (RTG2) and genes involved in diverse cellular
functions (activation of RNA polymerase II transcription, calcium homeostasis, ribosomal biogenesis,
mitochondrial function, nuclear ubiquitin ligase function, and cell wall biosynthesis). Similarly, using a
mutant defective in calcium uptake, the same authors noticed that the strains with a flaw in a putative
plasma membrane calcium channel were modestly more susceptible to fluconazole, but revealed a
significant loss of viability upon prolonged fluconazole exposure. This result suggests that calcium
signalling is necessary for the survival of azole stress in C. glabrata and that, in the absence of Ca2+
signalling, fluconazole has a fungicidal rather than a fungistatic effect on C. glabrata [99]. Another
azole-related resistance mechanism is the decreased affinity, or even incapacity, of these drugs to bind.
The high ability to upregulate ERG11, CDR1, and PDR1 expression is, normally, followed by azole
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exposure [100]. All the genes linked to the biosynthesis of ergosterol are likely to be upregulated in the
case of azole pressure, nonetheless, ERG 1, 3, 6, 7, 9, and especially ERG11, are the most studied ERG
genes. ERG11, which converts lanosterol into 4, 4-dimethylcolesta-8,14,24-trienol, is markedly more
mentioned as a central point regarding the increase of ergosterol bioproduction, in response to the
azole attack on the C. glabrata cell membrane [87,101]. Potential mechanisms for the azole resistance
include a small affinity of its lanosterol 14α-demethylase. The resistance mechanisms in ERG11 occur
through the acquisition of point mutations in the gene encoding for the Erg11. Quite a few mutations
in ERG11 have been described, but only a few are directly connected to azole resistance [102,103].
The overexpression or upregulation of the target enzyme of the azoles is also an important resistant
mechanism linked to azole drugs [55]. Recently, a study in three different hospitals in Poland was
developed in order to determine the mechanisms of resistance to azoles in C. glabrata clinical isolates
in this country [104]. The authors used a Sensititre Yeast One test and discovered that, from the
81 studied strains, 18 were resistant to fluconazole, and 15 were cross-resistant to all other azoles tested.
RT-qPCR studies showed that 13 of 15 azole-resistant strains presented upregulation of the CDR1 gene
encoding the efflux pump, but no upregulation of the expression of CDR2. Also, no upregulation of
the ERG11 gene was observed. This study confirms that the gene profile of the resistant isolates of
C. glabrata azoles is variable between countries and strains, although certain genes are commonly up or
downregulated [104]. Miyazaki et al. [99] studied the effects of calcineurin, a serine-threonine-specific
protein phosphatase [105]. This protein emerged as a new target of antifungal therapy founded on
studies in several pathogenic fungi, probably because azole antifungals and calcineurin inhibitors
have mild synergistic effects against C. glabrata wild-type strains [98,106,107]. The results of this group
have shown that the C. glabrata calcineurin mutant presented augmented susceptibility to azoles and
cell wall-damaging agents and had lower virulence. Though the mutant lacking Crz1 presented a cell
wall-associated phenotype intermediate to that of the calcineurin mutant and was modestly reduced
in virulence, it did not improve azole susceptibility, thereby suggesting that calcineurin regulates both
Crz1-dependent and independent pathways depending on the type of stress [99]. Chen et al. [108]
disclosed that AP1 (which encodes a transcription factor related to stress responses) plays a critical role
in reaction to various stresses in C. glabrata and decreases the stress through transcriptional activation
of its target genes, including FLR1. The deletion of this gene only caused an amplified sensitivity to
fluconazole. Candida glabrata clinical isolates are known to have the aldo-keto-reductase superfamily
upregulated in the resistant isolates. RT-qPCR analysis revealed a AKR mRNA expression twice of
that seen in the sensitive isolates, associated with increased fluconazole and itraconazole resistance,
thus suggesting that upregulation of the AKR gene might give a new insight into the mechanism of
azole resistance [49,109]. Although isolation of such C. glabrata mutants from patients has been rarely
reported, Ferrari et al. [92] have successfully characterized two sequential and related C. glabrata isolates
recovered from the same patient undergoing azole therapy: BPY40 (azole susceptible) and BPY41
(azole resistant). BPY41 had a mitochondrial dysfunction with upregulation of the ABC-transporter
genes of C. glabrata. Testing the virulence of the “petite mutants” in mice with systemic and vaginal
murine infection models, the authors showed that, even with in vitro growth deficiency, BPY41 was
more virulent than BPY40. The authors also found an increase in the oxido-reductive metabolism
and in the stress response in BPY41, which was consistent with mitochondrial dysfunction, and that
certain genes involved in cell wall adaptation were upregulated in BPY41 compared to BPY40 [92].
Finally, Taff et al. [110] identified two glucan transferases and an exo-glucanase that deliver glucan
from the cell to the extracellular matrix, playing a biofilm-specific role, by mediating the distribution
and organization of mature biofilm matrix.
2.2. Polyene’s Resistance
The first cases of resistance to amphotericin B arose in parallel with the increase in the
number of invasive infections caused by several genus of fungi, many of them with primary
or intrinsic resistance to amphotericin B and usually associated with a high mortality [111–113].
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Although C. glabrata is frequently considered to be susceptible to amphotericin B, it has a clear tendency
to have higher minimum inhibitory concentration (MIC) values to polyenes than C. albicans [76,114].
Polyene resistance is still poorly understood and not well documented, particularly in C. glabrata,
but the molecular mechanisms primarily include the replacement of some or all of the polyene-binding
sterols, and the reorientation or the camouflaging of studying a clinical isolate of C. glabrata. Vandeputte
and colleagues [115] revealed lower ergosterol content in its membrane in comparison to the wild
type, and also found a nonsense mutation in the ERG6 gene that leads to a decrease in ergosterol
content. Discrepancies of the cell wall were also observed, which were associated with developed
susceptibility to cell wall-perturbing agents, with a high rate of cell mortality [115]. In another
clinical isolate of C. glabrata recovered from a patient treated with amphotericin B and with a poor
susceptibility to polyenes, a deficiency of ergosterol and an accumulation of late sterol intermediates
was detected, emphasizing a defect in the final steps of the ergosterol pathway. Sequencing exposed a
unique missense mutation in ERG6 (substitution of a cysteine by a phenylalanine in the corresponding
protein). RT-qPCR demonstrated an overexpression of the genes that encode enzymes involved in late
steps of the ergosterol pathway. The complementation of this strain with a wild-type copy of the ERG6
gene regenerated the susceptibility to polyenes and the standard morphology [116].
2.3. Echinocandin’s Resistance
Echinocandins are the first-line agents in the treatment of candidaemia [74]. Three mechanisms
can induce the reduced echinocandin susceptibility [55]: acquired FKS mutations [117] which confer
low β-1,3-D-glucan synthase sensitivity, higher MIC values, and clinical failure [118]; adaptive stress
responses, which result in high cell wall chitin content with a paradoxical growth in vitro [119]; and
finally, intrinsic FKS mutations, also resulting in elevated MIC levels (but in a lower level of reduced
β-1,3-D-glucan synthase sensitivity when compared with the acquired FKS mutations) [118,120,121].
The GAS gene family is also a regulator in the production of β-1,3 glucan in this species [52]. GAS1,
GAS2, and GAS5 are glycosylphosphatidylinositol (GPI)-anchored cell surface proteins [122], which are
involved in the production of β-1,3 glucan in C. glabrata [123]. A study performed from patients with
C. glabrata bloodstream infections showed that the resistance to echinocandins increased from 4.9% to
12.3% between 2001 and 2010. In addition, among the 78 fluconazole resistant isolates, 14.1% were
resistant to one or more echinocandin and almost 8% of the isolates had a FKS mutation (FKS1/FKS2
mutations), which appeared due to a prior echinocandin therapy. Additionally, nearly all revealed
intermediate or resistant MIC values to one echinocandin [124]. Thompson III et al. [125] performed
sequentiation of hot spots studies in 2008, known to confer echinocandin resistance, and the fallouts
revealed an F659V substitution within the FKS2 region of the glucan synthase complex [125]. Curiously,
micafungin MIC levels of C. glabrata FKS hot spot mutant isolates were observed to be less elevated
than those obtained for the other echinocandins, showing that the efficacy of micafungin could be
differentially dependent on specific FKS gene mutations [126]. Shields et al. [117] analysed several
echinocandin MIC levels and found that the average MICs values of caspofungin and anidulafungin
were higher for patients who failed therapy. Several Candida species isolates observed in vitro reflect a
curious high-dose paradox which is being linked to a complex network of pathways, causing slightly
elevated MIC levels, in which cells appear to regain susceptibility at high levels of a drug [127,128]. This
has the potential to contribute to clinical resistance [55] and it is extremely important to differentiate
these low-level drug tolerance and adaptive mechanisms from the Fks1-mediated mechanisms that
have been observed in clinical isolates and can result in treatment failure [55,129].
3. Resistance Mechanisms Related to Biofilms
Fungi in general, and Candida species in particular, are not motile microorganisms. The biofilm
structure, thus, reflects the sequence of cell division events that occur during a biofilm development
and results in an exceptionally resistant profile of the biofilm cells to one or several antifungal drugs.
The infections are complicated by the presence of robust inducible gene networks encoding different
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proteins that confer tolerance or resistances to many available antifungal drugs [130]. These resistances
can be classified as either microbiological or clinical [55]. The first is defined by the presence of
a developed or mutational resistance mechanism to a specific drug. It depends directly on the
microorganism and it is distributed into two groups: primary or innate, in which fungi are resistant
prior to drug exposure, and secondary or acquired, when it appears in response to a drug exposure.
Several general mechanisms of biofilm drug resistance are thought to confer resistance to
multiple classes of antifungals in Candida species biofilms: the up-regulation of efflux pumps,
cell wall composition, increased cell density and quorum sensing effect, presence of an extracellular
matrix, changes in metabolism, the presence of persister cells, and cellular signalling and stress
responses [101,130–133].
3.1. Up-Regulation of Efflux Pumps and Cell Wall Composition
Two main classes of efflux pumps contribute to antifungal drug resistance: the ATP binding
cassette (ABC) transporter superfamily containing CDR1 and CDR2, and the MFS superfamily
containing MDR1 [130,134,135]. While under treatment with antifungals, biofilm cells up-regulate
these transporters within six hours of surface contact both in vitro and in vivo, even in the absence of
drug [136–139]. In 2013, our group [41] described that the usual ABC transporters were upregulated
in biofilms of three C. glabrata strains. Similarly, another ABC transporter, PDR1, was evaluated and
was found to be overexpressed. These alterations were linked to modifications in the structure of
C. glabrata biofilms by creating cell clusters, which could be a possible mechanism of biofilm tolerance
to fluconazole. The surface adherence alone seems enough to intensify the expression of the genes
encoding the efflux pumps [140], which are also up-regulated in mature biofilms, demonstrating that
they continue to mediate drug resistance throughout biofilm development [141–143].
3.2. Increased Cell Density and Quorum Sensing
It is well recognized that the inoculum size can affect susceptibility results [130,144–147].
Thus, using the microtiter method to test Candida species for drug susceptibility, an optimal inoculum
size range was defined as a clinical standard. Indeed, if this cell concentration is augmented in the drug
resistance assays, resistance specifically to fluconazole, ketoconazole, amphotericin B, and caspofungin
is increased up to twenty-fold [147]. On the contrary, if biofilms are dissociated and analysed at a lower
density in the same assays, they show drug susceptibilities at the level of planktonic cells evaluated at
the same cellular density.
In the biofilm environment, Candida species cells have the ability to communicate with each
other via quorum sensing (via numerous signalling molecules), which is directly dependent on the cell
density [148].
3.3. Extracellular Matrix
In Candida species biofilms, carbohydrates, proteins, and nucleic acids form the extracellular
matrix that surround the cells in the biofilms [149–154]. It is thought that biofilms prevent, to a greater
or lesser extent, the penetration of antifungal drugs through their structure, by the establishment
of a diffusion barrier, which acts as an ion-exchange resin, binding charged antibiotic molecules,
contributing to biofilm drug resistance, including in the case of C. glabrata [44,150,155]. The most
important components are the β-glucans, which are polymers of the fungal cell wall and are a
substantial constituent of the biofilm Candida species matrix. When induced, the disruption of
β-1,3-glucans or a β-1,3-glucanase treatment have been shown to increase susceptibility of biofilms
to fluconazole and the addition of exogenous β-1,3 glucans has been demonstrated to result in the
rise of resistance to fluconazole in planktonic cells [155]. Additionally, it is possible that biofilms
can also sequester amphotericin B, as it has been shown that β-1,3-glucans can bind specifically to
this drug [44,156]. It is known that planktonic cells generally rely on irreversible genetic changes to
maintain a resistant phenotype, while biofilms are able to persist due to their physical presence and the
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density of the population, which affords an almost inducible resistant phenotype notwithstanding of
distinct genetic alterations [130,157]. The application of DNA microarray and proteomic technologies
can facilitate a more detailed analysis of the biofilm lifestyle [158,159] Specific biofilm formation genes
are being brought up regarding different roles in biofilm resistance: peroxisomal catalase (CTA1),
the biosynthesis and degradation of tyrosine genes (ARO), the muscle creatine kinase (MSK), the heat
shock protein 90 (HSP 90), the sphingolipid biosynthesis (SKN 1 and KRE1), SIR, RIF, and, finally,
the extracellular matrix (ECM) regulators: zinc regulated genes (ZAP1), g-carbonic anhydrase (GCAL1),
alcohol dehydrogenase (ADH5), and also cell surface hydrophobicity (CSH1) [130,159].
3.4. Metabolism and Stress Response
Alterations in temperature or specific nutrients, restricted nutrient availability, ionic stress, and
variations in osmolality and oxidative stress are all acknowledged as antifungal resistance mechanisms
of biofilms. A study showed that the resistance to chlorhexidine, fluconazole, amphotericin B, and
nystatin increased as biofilms mature over time, corresponding to a growth in metabolic activity over
biofilm maturation. However, in these experiments, cell number was not controlled, thus making it
unclear if this is a true demonstration of metabolic activity [159]. Baillie and Douglas [160] have shown
that, at lower growth rates, planktonic cells are more resistant to amphotericin B, and biofilms are
equally resistant over a range of growth rates, thereby suggesting that growth rate plays only a minor
role in Candida species biofilm drug resistance. In another study [161], the same authors demonstrated
that neither glucose nor iron limitation disturbs Candida species biofilm resistance to amphotericin
B. However, iron limitation increased the susceptibility of dispersed daughter cells from biofilms to
amphotericin B, detected by a number of cells which induce responses by signalling pathways [162].
Seneviratne et al. [163] showed that there is a positive regulatory protein response associated with
the stress response in biofilms of stressed C. glabrata, as displayed by the heat shock and other stress
proteins (Hsp12, Trx1, and Pep4).
3.5. Persister Cells
Inside the biofilm cell population, persister cells form a unique group that is formed randomly,
phenotypically dormant, highly tolerant to antifungal drugs [164], and which is a key mechanism of
resistance in chronic infections [130]. Yeast persister cells were first discovered as a small population
in C. albicans biofilms [165,166]. These cells were extremely drug resistant in a manner that was
independent of drug efflux pumps and the composition of the cell membrane. Al-Dhaheri and
Douglas [166] reported persister cells in biofilms treated with amphotericin B from isolates of Candida
species. Candida species persister cells are exclusively recovered from biofilms and not from planktonic
populations, notwithstanding their growth phase, and involve attachment to a substrate to initiate the
dormant phenotype. These cells are believed to be a phenotypic variant of the wild type strain, for
they are the result of a biofilm with new subpopulations [133]. Bojsen and colleagues [167] performed
a study in order to evaluate whether resistance mechanisms on amphotericin B were shared between
biofilm and planktonic populations. A multiplexed barcode sequencing screening of a combined
group of gene-deletion mutants cultivated as biofilm and planktonic cells associated with an assay for
resistance to the ergosterol-targeting fungicide amphotericin B was executed. The results revealed that
the biofilm and planktonic population had substantial overlap in amphotericin B-persistent mutants.
Also, the authors were able to demonstrate that the mutants defective in sterol metabolism, ribosome
biosynthesis, and in the TORC1 (ubiquitin binding activity, role in cellular response to starvation,
regulation of cell growth, etc.) and in the Ras pathways (protein signal transduction) displayed
an amplified persistence when treated with amphotericin B. The ras1, ras2, and tor1 mutants had a
high-persister phenotype compared to wild-type biofilm and planktonic cells exposed to the TORC1
pathway inhibitor rapamycin, and, on the other hand, the inhibition of TORC1 with rapamycin similarly
improved the proportion of persisters in C. glabrata. With these results, the authors demonstrated that a
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decreased TORC1-mediated induction of ribosome biosynthesis via Ras can originate the development
of amphotericin B-persister cells in planktonic populations, but also in biofilms [167].
4. Cross and/or Multidrug Resistance
Antifungal drug resistance is particularly more serious when it develops not only against the
administered drug, but also to other non-related chemical compounds, and C. glabrata has emerged
as a major health threat since it also rapidly acquires resistance to multiple drug classes. The use
of echinocandins and development of cross-resistance is creating apprehension, for the signs of
multidrug resistance amongst azoles and echinocandins have already been described [168–170]. Studies
with clinical isolates obtained from patients in several epidemiological studies show that not only
has multiple antifungal resistance been described in isolated events, but also that cross-resistance
among more than one class of antifungal drugs is growing [171]. As a result, 11.1%–58.3% of
C. glabrata isolates resistant to echinocandins had cross resistance against fluconazole or other
azoles [168,169,172], and cross resistance of C. glabrata of echinocandins and amphotericin B have also
been reported [173]. Estimates regarding the percentage of non-susceptible or resistant C. glabrata
clinical isolates against four antifungal drugs used in clinical practice, across several geographic
regions are: fluconazole, 3.4%–70%; amphotericin B, 2.5%–60%; caspofungin, 1.3%–16.2%, and
5-flucytosine, 0.8%–35%, which are clearly concerning numbers [171,173–193]. Additionally, the
latest cross-resistance between amphotericin B and azoles or caspofungin in Candida species are
increasingly worrying [103,194–197]. Not in all cases, but in most of them, this multidrug resistance
phenomenon depends on the activity of ABC transporters and MFS [198], which are known to be
regulated by the Pdr1 transcription factor, which is recognized to be the major regulator of multidrug
resistance in C. glabrata [94]. As previously explained, C. glabrata expresses three ABC transporters
(CDR1, CDR2, and SNQ2). Studies revealed that the deletion of CDR1 in an azole-resistant strain leads
to the intracellular accumulation of fluconazole and hypersusceptibility to other azoles. The additional
CDR2 deletion worsens this phenotype [91,199]. Finally, the deletion of SNQ2 leads to an amplified
susceptibility to several azoles, but also to 4-nitroquinoline-N-oxide, in an azole-resistant strain [200].
Recently, Healey and colleagues [201] showed a mutator phenotype caused by a mismatch repair defect
which is prevalent in C. glabrata clinical isolates. These strains possess alterations in mismatch repair
gene MSH2 which leads them to display an advanced predisposition to develop antifungal treatment
in vitro and in mouse models of colonization. Also, the authors found that 55% of all C. glabrata that
are recovered from patients have these genetic characteristics, which is clinically very concerning.
The genetic mechanism involved in this process supports the acquisition of resistance to multiple
antifungals, partially explaining the higher rates of triazole and multidrug resistance associated with
C. glabrata [201]. Beforehand, Nishikawa and colleagues [202–204] identified an activator-targeted
KIX domain in the human MED15 Mediator subunit that is structurally conserved in Gal11/Med15
Mediator subunits in fungi. This Gal11/Med15 KIX domain is involved in Pdr1 orthologues and in the
clinically important C. glabrata multidrug resistance pathogenenis [205]. In a recent work, Nishikawa
et al. [204] implemented a sequential biochemical and in vivo high-throughput screens to identify
small-molecule inhibitors of the interaction of the C. glabrata Pdr1 activation domain with the C. glabrata
Gal11A KIX domain, which is linked to the C. glabrata multidrug resistance. Results showed that
iKIX1 inhibits Pdr1-dependent gene activation and re-sensitizes drug-resistant C. glabrata to azole
antifungals in vitro and in animal models for disseminated and urinary tract C. glabrata infection [204].
The sirtuins Sir2 and Hst1 control the expression of several genes including adhesins required for host
colonization and niacin transporters needed for growth in C. glabrata. With the knowledge that these
sirtuins can be inactivated during infection, Orta-Zavalza et al. [206] proved that their inhibition could
change the response of C. glabrata to other stressful conditions. The results showed that a deletion of
HST1 reduced the susceptibility of C. glabrata to fluconazole and hydrogen peroxide. Pdr1 and CDR1
mediated the fluconazole resistance phenotype of the ∆ hst1 cells, while the transcriptional activator
Msn4 and the catalase Cta1 were required to provide oxidative stress resistance. Also, the authors
J. Fungi 2017, 3, 11 11 of 30
showed that the transcription factor Sum1 interacts with Hst1 and participates in the regulation of
these genes. The findings state that Hst1 acts as a regulator of stress resistance associated-genes [206].
Candida species seems to tolerate stress induced by weak acids, which appears to be a key factor
in their persistence and virulence in antifungal drugs. MFS transporters are integrated into two
families: the DHA1 (drug: H+ antiporter family 1), with 12 transmembrane domains, and the DHA2
(drug: H+ antiporter family 2), with 14 transmembrane domains. Other transporters, Qdr2 and Tpo3,
have also been studied [198]. The first was acknowledged to be a cause of resistance to imidazoles
(e.g., clotrimazole, miconazole, tioconazole, and ketoconazole) and was proven to play an active part in
the efflux of these drugs. Its expression was found to be stimulated in clotrimazole-stressed cells, under
Pdr1 control [207]. The second was demonstrated to be linked to the resistance to both imidazoles
and triazoles (e.g., fluconazole), and to the polyamine spermine, found in high concentrations in the
urogenital tract. The authors also found that TPO3 was upregulated in C. glabrata cells exposed to
spermine, in a Pdr1-dependent manner [198]. Likewise, Tpo3 appears to be linked to the efflux of
azoles and spermine, and the control of the intracellular concentration of this polyamine appears
to be important for azole resistance [208]. Another MFS H+ antiporter, Aqr1, from C. glabrata, was
also identified by Costa et al. [209]. This MFS antiporter is a determinant of resistance to acetic acid,
flucytosine, and clotrimazole (frequently found in the vaginal mucosa, probably contributing to the
persistence in this niche). It is known that these antifungals act synergistically with acetic acid against
this pathogen. Aqr1 (located in plasma membrane and in the membrane vesicles) was suggested
to play a role in intermediating the extrusion of chemical compounds, dropping the intracellular
accumulation of 3H-flucytosine and, in a minor degree, of 3H-clotrimazole, which is reliable with
a direct role in antifungal drug efflux. When an AQR1 deletion was performed, no effect could be
noticed on the intracellular accumulation of 14C-acetic acid, thus suggesting that its role in acetic
acid resistance may be indirect, possibly through the transport of a so far undisclosed physiological
substrate. The pre-exposure to flucytosine or clotrimazole was found to make C. glabrata cells more
tolerant to acetic acid stress. Therefore, Costa et al. [209] showed that Aqr1 is an antifungal drug
resistance determinant and it may play an essential part in C. glabrata persistent colonization and
multidrug resistance.
Hull et al. [210] identified a clinical isolate of C. glabrata (CG156) that displayed flocculent growth
and cross-resistance to fluconazole, voriconazole, and amphotericin B. In this work, CG156 was found
to be a low-efflux isolate and when grown on sterol-supplemented, its cultures reached higher cell
densities, with shorter lag phases, and showed variations in cellular sterol composition that did not
affect its azole-resistant phenotype. When this isolate was grown in the presence of ergosterol, it
showed increased sensitivity to the polyene and when grown with cholesterol it became more resistant.
The results therefore indicate that some clinical isolates might persist as slow-growing agents of
chronic infections, possibly since they can survive without sterol auxotrophy; possess mutated Erg11;
lack cellular ergosterol (high-level resistance to polyenes); and can opportunistically exploit a wide
spectrum of host/environmental sterols for growth. The authors also indicate that the altered cellular
sterol composition of CG156 may affect intracellular signalling and trafficking pathways, as the efflux
machinery [199,211,212] and any transport proteins that are proposed to mediate azole import via
facilitated diffusion [213].
Other cases of induced cross-resistance to azole drugs in C. glabrata were related to resistance
against both azoles and amphotericin B [198,199,212] and related to prochloraz (an agricultural
antifungal). The original mechanism responsible for this phenomenon was found to be the upregulation
of multidrug transporters [214]. Also in C. glabrata, Flr1 has been proven to be involved in the resistance
of benomyl (a pesticide used in agriculture), but no connection was found between this transporter
and antifungal resistance [108].
Vermitsky and colleagues [94] showed that treatment with terbinafine (allylamines antifungal
class), which targets the enzyme squalene epoxidase in the ergosterol biosynthetic pathway, presented
upregulation on ERG11 as previously reported, however, unlike the azoles, this drug had minimal
J. Fungi 2017, 3, 11 12 of 30
effect on CDR1 and PDH1. Several studies with histatins have been performed, since these salivary
cationic proteins had been found to have effectiveness against diverse fungi [215–219]. Unfortunately,
further studies disclosed that they have expressively less activity against C. glabrata, with current
speculation suggesting that C. glabrata might escape histatin 5 activity by applying fermentative
pathways, as theoretically glucose can either be fermented or assimilated. Moreover, C. glabrata is a
Crabtree-positive fungus [220], thus its respiration could be negatively affected by certain levels of
glucose [221]. The same results that confirmed an apparently fundamental and extensive resistance of
C. glabrata to histatin 5 showed that it is not related to the resistance mechanisms of azoles.
5. Alternative Therapies for the Treatment of Infections Related to Candida glabrata
Considering the increasing number of Candida species with drug resistance, namely C. glabrata,
the identification of efficient alternative therapies to the current antifungal agents is crucial.
Many approaches are currently being pursued, including the development of novel antifungal agents,
the exploitation of the antimicrobial properties of plant derivatives and honey, and the development of
photodynamic therapy. An overview of the most recent advances in these approaches is provided in
the following paragraphs.
5.1. Plant Essential Oils and Extracts
Despite the efforts to discover novel and more efficient chemical antifungal molecules, these are
often associated with a variety of adverse side effects. This prompted the search for safer alternatives,
among which are plants. Medicinal plants have been used since ancient times for therapeutic purposes.
For example, superficial candidiasis is traditionally treated with a topical application of calendula and
commiphora [222]. Currently, these plants are being investigated to determine the active principles
responsible for their therapeutic effects and to understand how to apply these principles for antifungal
treatment [223–225]. Several plant secondary metabolites such as tannins, terpenoids, alkaloids,
flavonoids, and glycosides have been found to have antimicrobial properties in vitro [226,227]. Plant
antifungal properties are less explored than antibacterial properties, but they are thought to derive
from the same secondary metabolites. To explore the antifungal potential of plants, both essential
oils and plant extracts have been used. Both are promising antifungal agents because of their relative
safety, wide acceptance (a consequence of the traditional use), and are renewable in nature [228–230].
Plant essential oils are odorous volatile natural complex compounds. They are found only
in 10% of the plant kingdom [231] and are generally in low quantities (rarely exceeding 1% of
the plant mass) [232]. They are typically recovered from plants by distillation methods, are
hydrophobic [233,234], and are composed of variable mixtures of many compounds (e.g., terpenoids
such as alcohols, esters, aldehydes, ketones, ethers, phenols and epoxides, and low molecular weight
aliphatic hydrocarbons [235,236]).
Likewise, plant extracts are of complex composition. These can be extracted from different plant
organs, giving rise to a variable composition (in components and quantities) and therefore therapeutic
effect. For example, Mirtus communis L. (myrtle) leaf and flower extracts are rich in tannins while the
stem is rich in flavonoids [237]. Furthermore, the composition of the extracts is also variable according
to the solvent used for extract preparation [238].
Several plant essential oils and extracts have been investigated for possible antifungal properties.
These include those obtained from Origanum vulgare (oregano), Cinnamomum zeylanicum (cinnamon),
Lippia graveolens (Mexican oregano), Thymus vulgaris (thyme), Salvia officinalis (sage), Rosmarinus
officinalis (rosemary), Ocimum basilicum (basil), Zingiber officinale (ginger), Eucalyptus globulus (blue
gum), Juglans regia (walnut), Pterospartum tridentatum (common poppy), Rubus ulmifolius (blackberry),
and Glycyrrhiza glabra L. (licorice). Antimicrobial activity against C. glabrata isolates was observed for
Origanum vulgare, Lippia graveolens, and Cinnamomum zeylanicum essential oils, with the first two being
more active against fluconazole-susceptible C. glabrata, and the latter showing the best antifungal
activity against the fluconazole-resistant C. glabrata isolates [239]. Extracts from Juglans regia, Eucalyptus
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globulus, Pterospartum tridentatum, and Rubus ulmifolius were also effective against several Candida
species, especially C. glabrata, followed by C. albicans, C. parapsilosis, and C. tropicalis. The effects
of Juglans regia and Eucalyptus globulus were assessed in more detail revealing a fungistatic and not
fungicidal activity [240]. Glycyrrhiza glabra extracts have shown promising inhibitory results against
several Candida strains, especially C. tropicalis and C. glabrata. These extracts have also demonstrated
anti-biofilm activity against the two Candida species, although a double concentration of extract was
generally required to obtain an antifungal effect in biofilm similar to that of planktonic cells [241].
In summary, plant essential oils and extracts are promising alternatives to current chemical
antifungal agents. However, it is important to note that the establishment of standards for the
therapeutic use of these plant derivatives to treat Candida species infections will require overcoming
the variation in composition between samples, resulting from a multitude of factors that include,
but are not restricted to, genotype, cultivation area, time of harvesting, and processing methods [242].
5.2. Honey
Honey is a natural sweet substance produced by honeybees from the nectar of flowers or from
secretions of living parts of plants, which are transformed in the upper aero-digestive tract of the bee.
Consequently, the chemical composition of honey varies depending on the botanical source. Honey is
then stored in the honeycomb where it ripens and matures [243].
The first human use of honey traces back to 8000 years ago. Since then, honey has played
an important role in traditional medicine, and is now also finding its place in modern medicine.
In fact, studies have reported the bactericidal, bacteriostatic, antiviral, antioxidant, anti-inflammatory,
and anti-tumoral properties of honey [244–247]. However, although a number of studies have
investigated the antimicrobial properties of honey against bacteria, few have focused on its antifungal
properties [248–253]. Nevertheless, the few reports currently available show promising results.
Irish et al. [250] evaluated three floral honeys (Jarrah honey, Medihoney Antibacterial Honey Barrier,
Comvita Would Care 18+) and one artificial honey simulating honey’s typical high sugar levels against
C. albicans, C. glabrata, and C. dubliniensis. They found that C. dubliniensis was the most susceptible
species to the activity of honey, while C. glabrata was the least susceptible. They also reported greater
antifungal activities of the floral honeys compared to the artificial honey. This observation was
also reported in the study of Estevinho et al. [243], where a synthetic honey solution was tested
to determine the antifungal activity that was attributable to sugars, only to find that the activity
was reduced compared to natural honey. It is therefore suggested that the component(s) of honey
responsible for the antifungal properties are not sugar based.
Additional in vitro and in vivo evaluations are necessary to fully assess the antifungal potential
of honey. For in vivo applications, honey may be limited to topical treatments, not being a viable
option to treat candidaemia. However, honey may be used prophylactically to prevent more serious
infections. A few studies have already demonstrated this possibility. For example, prevention of
exit site infection by coating catheters with honey was found to be at least as effective as povidone
iodine [254] or mupirocin [255].
5.3. Photodynamic Therapy (PDT)
Many studies have investigated the use of photodynamic therapy (PDT) to fight fungi
infections [256]. PDT uses a photosensitive substance activated by a light source of a specific
wavelength. The activation of photosensitizers added to cells and microorganisms, by an appropriate
wavelength of light in the presence of oxygen, promote a phototoxic response of the cells, usually via
oxidative damage [257]. The PDT sensitization depends on the parameters related to the concentration,
time of incubation, and type of photosensitizer, as well as the physiological state of the microorganisms,
time of exposure, and energy density of the laser [258,259]. Although photodynamic approaches are
well established experimentally for the treatment of certain cutaneous infections, there is limited
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information about their mechanism of action for specific pathogens as well as the risks to healthy
tissues [260].
The action of different photosensitizers, mainly phenothiazine dyes, porphyrins,
and phthalocyanines, has been investigated. Many studies have demonstrated the efficacy of
phenothiazine dyes such as methylene blue, new methylene blue, and toluidine blue in PDT for the
reduction of fungi [256,258,259,261]. Malachite green, a cationic dye of the triarylmethane family
(e.g., crystal violet) is another option for a photosensitizer. These dies have been shown to effectively
reduce the number of Candida species cells. Dovigo et al. [262] observed that the fungicidal effect of
PDT was strain-dependent. Significant decreases in biofilm viability were observed for three strains of
C. albicans and for two strains of C. glabrata. Moreover, single-species biofilms were less susceptible to
PDT than their planktonic counterparts.
As a consequence of the use of non-specific oxidizing agents, organisms resistant to conventional
antifungal agents may be successfully killed by PDT and the development of resistance to this therapy
seems unlikely, making this a very promising therapy [257]. In fact, the data to date suggests that
photodynamic treatment approaches hold great promise for combating certain fungal pathogens.
5.4. Antifungal Agents with New Targets and New Sources
As a consequence of the increasing resistance demonstrated by Candida species to the currently
available antifungal drugs, efforts are being made to develop novel and more effective antifungals.
Different molecules are being discovered, synthesized, and evaluated for their capacity to control
Candida species growth. For example, Vartak et al. [263] isolated a new polyene macrolide antibiotic
from the fermentation broth of Streptomyces species. After purification, they evaluated the antimicrobial
activity against several fungi (Aspergillus fumigatus, C. albicans, C. krusei, C. glabrata, Cryptococcus
neoformans, Trichophyton species, and fluconazole-resistant C. krusei and C. glabrata strains) and
Gram-positive and Gram-negative bacteria. They found the polyene macrolide to be specifically
active against fungi, being unable to inhibit bacterial growth.
Glucosides modified in their saccharide units have been synthesized and their activity against
Candida species evaluated by de Souza et al. [264]. One of the modified glucosides showed
promising results, with fungistatic (threefold higher than fluconazole) and fungicidal activity
against C. glabrata. The authors consider this compound to be a novel structural pattern in the
development of new antifungal drugs. Different aldehydes, hydrazones, and hydrazines have
also been assessed against several Candida species, among which 4-pyridin-2-ylbenzaldehyde and
tert-butyl-(2Z)-2-(3,4,5-trihydroxybenzylidine)hydrazine carboxylate have shown the most promising
results [265]. The activity of these compounds is thought to be on the fungal membrane. A series of
fatty N-acyldiamines, prepared from fatty methyl esters and 1,2-ethylenediamine, 1,3-propanediamine,
or 1,4-butanediamine, have also demonstrated moderate to good antifungal activity against C. albicans,
C. tropicalis, C. glabrata, and C. parapsilosis [266].
Abrão et al. [267] evaluated the anti-candidal activity of new Mannich base-type eugenol
derivatives and found that 4-allyl-2-methoxy-6-(morpholin-4-ylmethyl) phenyl benzoate and
4-{5-allyl-2[(4-chlorobenzoyl)oxy]-3-methoxybenzyl}morpholin-4-ium chloride were the most effective,
particularly against C. glabrata, C. albicans, and C. krusei, with IC50 values below those of fluconazole.
Raman et al. [268] evaluated the activity of amphiphilic, helical β-peptide structural mimetics
of natural antimicrobial α-peptides against clinically isolated and drug resistant Candida strains.
Candida tropicalis was the most susceptible to the activity of the β-peptide, while C. glabrata was the
least susceptible. Interestingly, they report that β-peptides are mostly ineffective at disrupting Candida
species biofilms, but they can prevent the formation of C. albicans, C. glabrata, C. parapsilosis and
C. tropicalis biofilms. β-peptides thus seem to be a promising class of molecules to use as therapeutics.
Silva-Dias et al. [269] evaluated the antifungal properties of cerium, a lanthanide member, against
planktonic and sessile Candida cells. The activity of cerium appears to result from severe cellular
metabolic activity impairment and membrane damage. This compound was shown to effectively
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prevent biofilm formation both in vitro and in vivo in segments of polyurethane catheters in mouse
models, and also to almost eradicate established biofilms when used at high concentrations. Cerium
is therefore suggested as a possible antifungal agent to prevent the formation of biofilm-associated
infections in clinical settings, for example, by catheter coating.
Additionally, antibacterial agents are being evaluated for their antifungal activity. For example,
chloramphenicol, a bacteriostatic antibiotic, was evaluated against 30 representative yeast strains [270].
The antifungal activity of chloramphenicol was comparable to other known antifungal compounds
(e.g., caspofungin acetate, ketoconazole, and metronidazole). However, it had no activity against most
C. albicans tested, as well as C. famata, C. glabrata, C. haemolonei and Cryptococcus neoformans.
The combination of common antifungal agents with other antifungal molecules is also being
assessed. For example, Ning et al. [271] has shown that the combination of epigallocatechin gallate
(EGCG) with miconazole, fluconazole, or amphotericin B has a synergistic effect against planktonic
and biofilm cells of Candida species (Fractional inhibitory concentrations (FIC) ≤ 50). They suggest that
combined treatment of antifungal agents and EGCG may lower the dosages of antimycotics necessary
to treat infections, thus preventing possible adverse effects and the emergence of resistant strains.
Another approach under consideration is the design of drugs with extended persistence and
controlled release. For this purpose, nanotechnology creates new possibilities. For example,
Perera et al. [272] evaluated the encapsulation of citric acid into a Mg-Al-layered double hydroxide
(LDH). Citric acid has antifungal properties and its encapsulation would allow its slow release in
topical skin formulations. The nanoparticles obtained were introduced into a body cream formulation,
which demonstrated a prolonged slow release up to 8 h in aqueous medium under different pH values
(3–5). The same body cream demonstrated an improved antifungal activity against C. albicans and
C. glabrata, but not C. tropicalis. Also, Silva et al. [273] presented results with silver nanoparticles having
a significant effect on reducing C. glabrata biofilm.
Defence mutualisms between social insects and microorganisms have been also largely studied,
since the symbiotic nature of endophytic microorganisms favours metabolic interactions with their
host and their environment, increasing the production of bioactive compounds [274]. Nirma et al. [275]
reported the discovery of a Pseudallescheria boydii strain isolated from Nasutitermes species The microbial
symbiont produces two metabolites with antifungal activity: tyroscherin and N-methyltyroscherin,
shown to be effective antifungal agents with favourable selectivity indices for C. albicans and
C. parapsilosis. Later, the same authors [276] discovered ilicicolinic acids A, C, and D and ilicicolinal
isolated from a fungus (Neonectria discophora SNB-CN63) that was isolated from a termite (Nasutitermes
corniger) nest in French Guiana, which showed in vitro against the same Candida species. Also in French
Guiana, other authors [274] isolated fungi and bacteria from plants. Three active fungal extracts were
fractionated, resulting in the isolation of eight compounds, which exhibited antifungal and cytotoxic
potential against C. albicans ATCC10213.
6. Conclusions
Fungal infections have been increasing significantly in recent years, contributing to high morbidity
and mortality, especially in immunocompromised individuals. The quick rise in the incidence of single,
cross, and multidrug antifungal resistance within C. glabrata strains make it crucial to further increase
the data on the virulence and resistance mechanisms associated with this species. Also, the capacity
to form biofilms is one of the most important features in Candida species pathogenicity, creating
a dangerous prospect of ineffective therapies against these infections. Candida glabrata biofilms are
extremely refractory to antimicrobial therapy and more difficult to manage due to the natural properties
mode of growth. They are able to withstand much higher concentrations of antifungal drugs compared
with the planktonic cells, making C. glabrata biofilm infections extremely challenging to treat.
The research for an improved comprehension on the mechanisms of drug resistance, but also
the search for alternatives to antifungal therapies, is becoming more important over time. Figure 2
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Figure 2. Mechanisms of antifungal resistance and alternatives therapies associated to C. glabrata biofilms. 
Acknowledgments: This work was supported by the Programa Operacional, Fatores de competitividade—
COMPETE and by national funds through FCT—Fundação para a Ciência e a Tecnologia on the scope of the 
projects FCT PTDC/SAU-MIC/119069/2010, RECI/EBB-EBI/0179/2012, and PEst-OE/EQB/LA0023/2013, Célia F. 
Rodrigues’ SFRH/BD/93078/2013 PhD grant, Maria Elisa Rodrigues’ Grant SFRH/BD/93078/2013. The authors 
thank the Project “BioHealth—Biotechnology and Bioengineering approaches to improve Programa Operacional 
Regional do Norte (ON.2—O Novo Norte), QREN, FEDER. 
Author Contributions: All authors contributed to the script. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Fidel, P.; Vazquez, J.; Sobel, J. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease 
with comparison to C. albicans. Clin. Microbiol. Rev. 1999, 12, 80–96. 
2. Introduction and historical perspectives. In Candida and Candidiasis; Calderone, R., Ed.; ASM Press, 
Washington D.C., WA, USA, 2002; pp. 15–25. 
3. Larone, H. Medically important fungi: A guide to identification.; 4th ed.; ASM Press: Washington, WA, USA, 
2002. 
4. Silva, S.; Negri, M.; Henriques, M.; Oliveira, R.; Williams, D.W.; Azeredo, J. Candida glabrata, Candida 
parapsilosis and Candida tropicalis: Biology, epidemiology, pathogenicity and antifungal resistance. FEMS 
Microbiol. Rev. 2012, 36, 288–305. 
5. Odds, F. Candida and Candidiasis; 2nd ed.; London: Baillierir Tindall., 1988. 
6. Dujon, B.; Sherman, D.; Fischer, G.; Durrens, P.; Casaregola, S.; Lafontaine, I.; de Montigny, J.; Marck, C.; 
Neuvéglise, C.; Talla, E.; et al. Genome evolution in yeasts. Nature 2004, 430, 35–44. 
Figure 2. Mechanisms of antifungal resistance and alternatives therapies associated to C. glabrata biofilms.
Acknowledgments: This work was supported by the Programa Operacional, Fatores de competitividade—COMPETE
and by national funds through FCT—Fundação para a Ciência e a Tecnologia on the scope of the projects FCT
PTDC/SAU-MIC/119069/2010, RECI/EBB-EBI/0179/2012, and PEst-OE/EQB/LA0023/2013, Célia F. Rodrigues’
SFRH/BD/93078/2013 PhD grant, Maria Elisa Rodrigue ’ Grant SFRH/BD/93078/2013. The authors thank the
Project “BioHealth—Biotechnology and Bioengineering approaches to improve Programa Operacional Regional
do Norte (ON.2—O Novo Norte), QREN, FEDER.
Author Contributions: All authors contributed to the script.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Fidel, P.; Vazquez, J.; Sobel, J. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease
with comparison to C. albicans. Clin. Microbiol. Rev. 1999, 12, 80–96.
2. Introduction and historical perspectives. In Candida and Candidiasis; Calderone, R., Ed.; ASM Press:
Washington, DC, USA, 2002; pp. 15–25.
3. Larone, H. Medically Important Fungi: A Guide to Identification, 4th ed.; ASM Press: Washington, DC, USA, 2002.
4. Silva, S.; Negri, M.; Henriques, M.; Oliveira, R.; Williams, D.W.; Azeredo, J. Candida glabrata,
Candida parapsilosis and Candida tropicalis: Biology, epidemiology, pathogenicity and antifungal resistance.
FEMS Microbiol. Rev. 2012, 36, 288–305. [CrossRef] [PubMed]
J. Fungi 2017, 3, 11 17 of 30
5. Odds, F. Candida and Candidiasis, 2nd ed.; Baillierir Tindall.: London, UK, 1988.
6. Dujon, B.; Sherman, D.; Fischer, G.; Durrens, P.; Casaregola, S.; Lafontaine, I.; de Montigny, J.; Marck, C.;
Neuvéglise, C.; Talla, E.; et al. Genome evolution in yeasts. Nature 2004, 430, 35–44. [CrossRef] [PubMed]
7. Brunke, S.; Hube, B. Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell. Microbiol.
2013, 15, 701–708. [CrossRef] [PubMed]
8. Kaur, R.; Domergue, R.; Zupancic, M.L.; Cormack, B.P. A yeast by any other name: Candida glabrata and its
interaction with the host. Curr. Opin. Microbiol. 2005, 8, 378–384. [CrossRef] [PubMed]
9. Hajjeh, R.A.R.A.; Sofair, A.N.A.N.; Harrison, L.H.L.H.; Lyon, G.M.M.; Arthington-Skaggs, B.A.B.A.;
Mirza, S.A.S.A.; Phelan, M.; Morgan, J.; Lee-Yang, W.; Ciblak, M.A.M.A.; et al. Incidence of bloodstream
infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a
population-based active surveillance program. J. Clin. Microbiol. 2004, 42, 1519–1527. [CrossRef] [PubMed]
10. Rodrigues, C.F.; Silva, S.; Henriques, M. Candida glabrata: A review of its features and resistance. Eur. J. Clin.
Microbiol. Infect. Dis. 2014, 33, 673–688. [CrossRef] [PubMed]
11. Colombo, A.L.; Guimaraes, T.; Silva, L.R.B.F.; Monfardini, L.P.; de Almeida Monfardini, L.P.; Cunha, A.K.B.;
Rady, P.; Alves, T.; Rosas, R.C. Prospective observational study of candidemia in Sao Paulo, Brazil: Incidence
rate, epidemiology, and predictors of mortality. Infect. Control Hosp. Epidemiol. 2007, 28, 570–576. [CrossRef]
[PubMed]
12. Bassetti, M.; Righi, E.; Costa, A.; Fasce, R.; Molinari, M.P.; Rosso, R.; Pallavicini, F.B.; Viscoli, C.; Pfaller, M.;
Diekema, D.; et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect. Dis.
2006, 6, 21. [CrossRef] [PubMed]
13. Hasan, F.; Xess, I.; Wang, X.; Jain, N.; Fries, B.C. Biofilm formation in clinical Candida isolates and its
association with virulence. Microbes Infect. 2009, 11, 753–761. [CrossRef] [PubMed]
14. Krcmery, V.; Barnes, A.J. Non-albicans Candida spp. Causing fungaemia: pathogenicity and antifungal
resistance. J. Hosp. Infect. 2002, 50, 243–260. [CrossRef] [PubMed]
15. Krcmery, V. Torulopsis glabrata an emerging yeast pathogen in cancer patients. Int. J. Antimicrob. Agents 1999,
11, 1–6. [CrossRef]
16. Tortorano, A.M.; Kibbler, C.; Peman, J.; Bernhardt, H.; Klingspor, L.; Grillot, R. Candidaemia in Europe:
epidemiology and resistance. Int. J. Antimicrob. Agents 2006, 27, 359–366. [CrossRef] [PubMed]
17. Sardi, J.; Scorzoni, L.; Bernardi, T.; Fusco-Almeida, A.; Mendes Giannini, M. Candida species: Current
epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.
J. Med. Microbiol. 2013, 62, 10–24. [PubMed]
18. Lim, C.S.-Y.; Rosli, R.; Seow, H.F.; Chong, P.P. Candida and invasive candidiasis: back to basics. Eur. J. Clin.
Microbiol. Infect. Dis. 2012, 31, 21–31. [CrossRef] [PubMed]
19. Abi-Said, D.; Anaissie, E.; Uzun, O.; Pinzcowski, H.; Vartivarian, S. The epidemiology of hematogeneous
candidiasis caused by different Candida species. Clin. Infect. Dis. 1997, 24, 1122–1128. [CrossRef] [PubMed]
20. Martins, M.; Lozano-Chiu, M.; Rex, J. Declining rates of oropharyngeal candidiasis and carriage of
Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in
human immunodeficiency virus-infected patients. Clin. Infect. Dis. 1998, 27, 1291–1294. [CrossRef] [PubMed]
21. Beck-Sague, C.; Jarvis, W. National nosocomial infectious surveillance system. Secular trends in the
epidemiology of nosocomial fungal infections in the United States, 1980–1990. J. Infect. Dis. 1993, 167,
1247–1251. [CrossRef] [PubMed]
22. Rees, J.; Pinner, R.; Hajjeh, R.; Brandt, M.; Reingold, A. The epidemiological features of invasive mycotic
infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance.
Clin. Infect. Dis. 1998, 7, 1138–1147. [CrossRef]
23. Pfaller, M.; Jones, R.; Messer, S.; Edmond, M.; Wenzel, R. National surveillance of nosocomial blood stream
infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal
susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 1998, 30, 121–129. [CrossRef]
24. Pfaller, M.A.; Jones, R.N.; Doern, G.V.; Sader, H.S.; Messer, S.A.; Houston, A.; Coffman, S.; Hollis, R.J.
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North
America and Latin America, 1997–1998. Antimicrob. Agents Chemother. 2000, 44, 747–751. [CrossRef]
[PubMed]
25. Gumbo, T.; Isada, C.; Hall, G.; Karafa, M.; Gordon, S. Candida glabrata fungemia. Clinical features of 139
patients. Medicine 1999, 78, 220–227. [CrossRef]
J. Fungi 2017, 3, 11 18 of 30
26. Pfaller, M.; Jones, R.; Doern, G.; Fluit, A.; Verhoef, J.; Sader, H.; Messer, S.; Houston, A.; Coffman, S.;
Hollis, R. International surveillance of blood stream infections due to Candida species in the European
SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole
and echinocandin agents. SENTRY Participant Group (Euro). Diagn. Microbiol. Infect. Dis. 1999, 35, 19–25.
[CrossRef]
27. Rodriguez-Tudela, J.; Cuenca-Estrella, M. Estudio multicéntrico sobre funguemias por levaduras en España
(abril-junio de 1997). Grupo de trabajo para el estudio de las funguemias. Rev. Clin. Esp. 1999, 199, 356–361.
[PubMed]
28. Pfaller, M.; Diekema, D.; Jones, R.; Sader, H.; Fluit, A.; Hollis, R.; Messer, S.; Group, T.S.P. International
surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro
susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through
1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 2001, 39, 3254–3259. [CrossRef]
[PubMed]
29. Wingard, J. Importance of Candida species other than C. albicans as pathogens in oncology patients.
Clin. Infect. Dis. 1995, 20, 115–125. [CrossRef] [PubMed]
30. Rex, J.; Pfaller, M.; Barry, A.; Nelson, P.; Webb, C. Antifungal susceptibility testing of isolates from a
randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients
with candidemia. Antimicrob. Agents Chemother. 1995, 39, 40–44. [CrossRef] [PubMed]
31. Abbas, J.; Bodey, G.P.; Hanna, H.A.; Mardani, M.; Girgawy, E.; Abi-Said, D.; Whimbey, E.; Hachem, R.;
Raad, I. Candida krusei fungemia. An escalating serious infection in immunocompromised patients.
Arch. Intern. Med. 2000, 160, 2659–2664. [CrossRef] [PubMed]
32. Vazquez, J.A.; Sanchez, V.; Dmuchowski, C.; Dembry, L.M.; Sobel, J.D.; Zervos, M.J. Nosocomial acquisition
of Candida albicans: an epidemiologic study. J. Infect. Dis. 1993, 168, 195–201. [CrossRef] [PubMed]
33. Vazquez, J.A.; Dembry, L.M.; Sanchez, V.; Vazquez, M.A.; Sobel, J.D.; Dmuchowski, C.; Zervos, M.J.
Nosocomial Candida glabrata colonization: An epidemiologic study. J. Clin. Microbiol. 1998, 36, 421–426.
[PubMed]
34. Martins, M.; Henriques, M.; Ribeiro, A.P.; Fernandes, R.; Gonçalves, V.; Seabra, Á.; Azeredo, J.; Oliveira, R.
Oral Candida carriage of patients attending a dental clinic in Braga, Portugal. Rev. Iberoam. Micol. 2010, 27,
119–124. [CrossRef] [PubMed]
35. Masiá Canuto, M.; Gutiérrez Rodero, F.; Ortiz de la Tabla Ducasse, V.; Hernández Aguado, I.;
Martín González, C.; Sánchez Sevillano, A.; Martín Hidalgo, A. Determinants for the development of
oropharyngeal colonization or infection by fluconazole-resistant candida strains in HIV-Infected Patients.
Eur. J. Clin. Microbiol. Infect. Dis. 2000, 19, 593–601. [CrossRef] [PubMed]
36. Redding, S.W.; Kirkpatrick, W.R.; Coco, B.J.; Sadkowski, L.; Fothergill, A.W.; Rinaldi, M.G.; Eng, T.Y.;
Patterson, T.F. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head
and neck cancer. J. Clin. Microbiol. 2002, 40, 1879–1881. [CrossRef] [PubMed]
37. De Bernardis, F.; Chiani, P.; Ciccozzi, M.; Pellegrini, G.; Ceddia, T.; D’Offizzi, G.; Quinti, I.; Sullivan, P.A.;
Cassone, A. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates
from oral cavities of subjects infected with human immunodeficiency virus. Infect. Immun. 1996, 64, 466–471.
[PubMed]
38. Fidel, P.L.; Cutright, J.L.; Tait, L.; Sobel, J.D. A murine model of Candida glabrata vaginitis. J. Infect. Dis. 1996,
173, 425–431. [CrossRef] [PubMed]
39. Negri, M.; Silva, S.; Henriques, M.; Oliveira, R. Insights into Candida tropicalis nosocomial infections and
virulence factors. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 1399–1412. [CrossRef] [PubMed]
40. Silva, S.; Henriques, M.; Martins, A.; Oliveira, R.; Williams, D.; Azeredo, J. Biofilms of non-Candida albicans
Candida species: Quantification, structure and matrix composition. Med. Mycol. 2009, 47, 681–689. [CrossRef]
[PubMed]
41. Fonseca, E.; Silva, S.; Rodrigues, C.F.; Alves, C.T.; Azeredo, J.; Henriques, M. Effects of fluconazole on
Candida glabrata biofilms and its relationship with ABC transporter gene expression. Biofouling 2014, 30,
447–457. [CrossRef] [PubMed]
42. Costerton, J.W.; Lewandowski, Z.; Caldwell, D.E.; Korber, D.R.; Lappin-Scott, H.M. Microbial Biofilms.
Annu. Rev. Microbiol. 1995, 49, 711–745. [CrossRef] [PubMed]
J. Fungi 2017, 3, 11 19 of 30
43. Donlan, R.; Costerton, J. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol.
Rev. 2002, 15, 167–193. [CrossRef] [PubMed]
44. Rodrigues, C.F.; Silva, S.; Azeredo, J.; Henriques, M. Candida glabrata’s recurrent infections: biofilm formation
during Amphotericin B treatment. Lett. Appl. Microbiol. 2016, 63, 77–81. [CrossRef] [PubMed]
45. Klotz, S.A.; Drutz, D.J.; Zajic, J.E. Factors Governing Adherence of Candida Species to Plastic Surfaces.
Infect. Immun. 1985, 50, 97–101. [PubMed]
46. Hazen, K.C.; Plotkin, B.J.; Klimas, D.M. Influence of growth conditions on cell surface hydrophobicity of
Candida albicans and Candida glabrata. Infect. Immun. 1986, 54, 269–271. [PubMed]
47. Kikutani, H.; Makino, S. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol.
1992, 51, 285–322. [PubMed]
48. De Las Peñas, A.; Pan, S.J.; Castaño, I.; Alder, J.; Cregg, R.; Cormack, B.P. Virulence-related surface
glycoproteins in the yeast pathogen Candida glabrata are encoded in subtelomeric clusters and subject
to RAP1- and SIR-dependent transcriptional silencing. Genes Dev. 2003, 17, 2245–2258. [CrossRef] [PubMed]
49. Castano, I.; Pan, S.; Zupancic, M.; Hennequin, C.; Dujon, B.; Cormack, B. Telomere length control and
transcriptional regulation of subtelomeric adhesins in Candida glabrata. Mol. Microbiol. 2005, 55, 1246–1258.
[CrossRef] [PubMed]
50. Sundstrom, P. Adhesion in Candida spp. Cell. Microbiol. 2002, 4, 461–469. [CrossRef] [PubMed]
51. Filler, S.G. Candida–host cell receptor–ligand interactions. Curr. Opin. Microbiol. 2006, 9, 333–339. [CrossRef]
[PubMed]
52. de Groot, P.W.J.; Kraneveld, E.A.; Yin, Q.Y.; Dekker, H.L.; Gross, U.; Crielaard, W.; de Koster, C.G.; Bader, O.;
Klis, F.M.; Weig, M. The cell wall of the human pathogen Candida glabrata: differential incorporation of novel
adhesin-like wall proteins. Eukaryot. Cell 2008, 7, 1951–1964. [CrossRef] [PubMed]
53. Kraneveld, E.A.; de Soet, J.J.; Deng, D.M.; Dekker, H.L.; de Koster, C.G.; Klis, F.M.; Crielaard, W.;
de Groot, P.W.J. Identification and differential gene expression of adhesin-like wall proteins in
Candida glabrata biofilms. Mycopathologia 2011, 172, 415–427. [CrossRef] [PubMed]
54. Silva, S.; Negri, M.; Henriques, M.; Oliveira, R.; Williams, D.W.; Azeredo, J. Adherence and biofilm formation
of non-Candida albicans Candida species. Trends Microbiol. 2011, 19, 241–247. [CrossRef] [PubMed]
55. Alcazar-Fuoli, L.; Mellado, E. Current status of antifungal resistance and its impact on clinical practice.
Br. J. Haematol. 2014, 166. [CrossRef] [PubMed]
56. Cleveland, A.A.; Farley, M.M.; Harrison, L.H.; Stein, B.; Hollick, R.; Lockhart, S.R.; Magill, S.S.; Derado, G.;
Park, B.J.; Chiller, T.M. Changes in incidence and antifungal drug resistance in candidemia: Results from
population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin. Infect. Dis. 2012, 55,
1352–1361. [CrossRef] [PubMed]
57. Shahi, P.; Moye-Rowley, W.S. Coordinate control of lipid composition and drug transport activities is required
for normal multidrug resistance in fungi. Biochim. Biophys. Acta 2009, 1794, 852–859. [CrossRef] [PubMed]
58. Muller, H.; Thierry, A.; Coppée, J.-Y.; Gouyette, C.; Hennequin, C.; Sismeiro, O.; Talla, E.; Dujon, B.;
Fairhead, C. Genomic polymorphism in the population of Candida glabrata: gene copy-number variation and
chromosomal translocations. Fungal Genet. Biol. 2009, 46, 264–276. [CrossRef] [PubMed]
59. Thierry, A.; Bouchier, C.; Dujon, B.; Richard, G.-F. Megasatellites: a peculiar class of giant minisatellites in
genes involved in cell adhesion and pathogenicity in Candida glabrata. Nucleic Acids Res. 2008, 36, 5970–5982.
[CrossRef] [PubMed]
60. Barchiesi, F.; Falconi Di Francesco, L.; Arzeni, D.; Caselli, F.; Gallo, D.; Scalise, G. Electrophoretic Karyotyping
and Triazole Susceptibility of Candida glabrata Clinical Isolates. Eur. J. Clin. Microbiol. Infect. Dis. 1999, 18,
184–187. [CrossRef] [PubMed]
61. Kaufmann, C.S.; Merz, W.G. Electrophoretic karyotypes of Torulopsis glabrata. J. Clin. Microbiol. 1989, 27,
2165–2168. [PubMed]
62. Klempp-Selb, B.; Rimek, D.; Kappe, R. Karyotyping of Candida albicans and Candida glabrata from patients
with Candida sepsis. Mycoses 2000, 43, 159–163. [CrossRef] [PubMed]
63. Lin, C.Y.; Chen, Y.C.; Lo, H.J.; Chen, K.W.; Li, S.Y. Assessment of Candida glabrata strain relatedness by
pulsed-field gel electrophoresis and multilocus sequence typing. J. Clin. Microbiol. 2007, 45, 2452–2459.
[CrossRef] [PubMed]
J. Fungi 2017, 3, 11 20 of 30
64. Shin, J.H.; Chae, M.J.; Song, J.W.; Jung, S.-I.; Cho, D.; Kee, S.J.; Kim, S.H.; Shin, M.G.; Suh, S.P.; Ryang, D.W.
Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with
Candida glabrata candidemia. J. Clin. Microbiol. 2007, 45, 2385–2391. [CrossRef] [PubMed]
65. Magee, B.B.; Sanchez, M.D.; Saunders, D.; Harris, D.; Berriman, M.; Magee, P.T. Extensive chromosome
rearrangements distinguish the karyotype of the hypovirulent species Candida dubliniensis from the virulent
Candida albicans. Fungal Genet. Biol. 2008, 45, 338–350. [CrossRef] [PubMed]
66. Bader, O.; Schwarz, A.; Kraneveld, E.A.; Tangwattanachuleeporn, M.; Schmidt, P.; Jacobsen, M.D.; Gross, U.;
De Groot, P.W.J.; Weig, M. Gross karyotypic and phenotypic alterations among different progenies of the
Candida glabrata CBS138/ATCC2001 reference strain. PLoS ONE 2012, 7, e52218. [CrossRef] [PubMed]
67. Rai, M.N.; Balusu, S.; Gorityala, N.; Dandu, L.; Kaur, R. Functional genomic analysis of
Candida glabrata-macrophage interaction: role of chromatin remodeling in virulence. PLoS Pathog. 2012, 8,
e1002863. [CrossRef] [PubMed]
68. Jandric, Z.; Schuller, C. Stress response in Candida glabrata: pieces of a fragmented picture. Futur. Mirobiology
2011, 6, 1475–1484. [CrossRef] [PubMed]
69. Riera, M.; Mogensen, E.; d’Enfert, C.; Janbon, G. New regulators of biofilm development in Candida glabrata.
Res. Microbiol. 2012, 163, 297–307. [CrossRef]
70. Iraqui, I.; Garcia-Sanchez, S.; Aubert, S.; Dromer, F.; Ghigo, J.M.; d’Enfert, C.; Janbon, G. The YAK1P kinase
controls expression of adhesins and biofilm formation in Candida glabrata in a SIR4P-dependent pathway.
Mol. Microbiol. 2005, 55, 1259–1271. [CrossRef] [PubMed]
71. Lemke, A.; Kiderlen, A.F.; Kayser, O. Amphotericin B. Appl. Microbiol. Biotechnol. 2005, 68, 151–162.
[CrossRef] [PubMed]
72. Baginski, M.; Czub, J. Amphotericin B and its new derivatives-mode of action. Curr. Drug Metab. 2009, 10,
459–469. [CrossRef] [PubMed]
73. Botero, M.C.; Puentes-Herrera, M.; Cortés, J.A. Formas lipídicas de anfotericina. Rev. Chil. Infectol. 2014, 31,
518–527. [CrossRef] [PubMed]
74. Perlin, D.S. Resistance to echinocandin- class antifungal drugs. Drug Resist. Updat. 2007, 10, 121–130.
[CrossRef] [PubMed]
75. Debono, M.; Gordee, R.S. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 1994,
48, 471–497. [CrossRef] [PubMed]
76. Canuto, M.M.; Rodero, F.G. Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis. 2002, 2,
550–563. [CrossRef]
77. Maenza, J.; Merz, W.; Romagnoli, M.; Keruly, J.; Moore, R.; Gallant, J. Infection due to fluconazole- resistant
Candida in patients with AIDS: Prevalence and microbiology. Clin. Infect. Dis. 1997, 24, 28–34. [CrossRef]
[PubMed]
78. Laguna, F.; Rodríguez-Tudela, J.L.; Martínez-Súarez, J.V.; Polo, R.; Valencia, E.; Díaz-Guerra, T.M.; Dronda, F.;
Pulido, F.; Martínez-Suárez, J. Patterns of fluconazole susceptibility in isolates from human immunodeficiency
virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin. Infect. Dis. 1997, 24,
124–130. [CrossRef] [PubMed]
79. Revankar, S.G.; Kirkpatrick, W.R.; McAtee, R.K.; Dib, O.P.; Fothergill, A.W.; Redding, S.W.; Rinaldi, M.G.;
Patterson, T.F. Detection and significance of fluconazole resistance in oropharyngeal Candidiasis in human
immunodeficiency virus-infected patients. J. Infect. Dis. 1996, 174, 821–827. [CrossRef] [PubMed]
80. Wingard, J.; Merz, W.; Rinaldi, M.; Jonhson, T.; Karp, J.; Saral, R. Increase in Candida krusei infection among
patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
N. Engl. J. Med. 1991, 325, 1274–1277. [CrossRef] [PubMed]
81. Gutiérrez, F.; Wall, P.; Cohen, J. Trends in antifungal use and antifungal isolates in a university hospital
1990–1992. J. Hosp. Infect. 1995, 31, 149–152. [CrossRef]
82. Nguyen, M.L.H.; Peacock, J.E.; Morris, A.J.; Tanner, D.C.; Nguyen, M.L.H.; Snydman, D.R.; Wagener, M.M.;
Rinaldi, M.G.; Yu, V.L. The changing face of candidemia: emergence of non- Candida albicans species and
antifungal resistance. Am. J. Med. 1996, 100, 617–623. [CrossRef]
83. Van Bambeke, F.; Balzi, E.; Tulkens, P.M. Antibiotic Efflux Pumps. Biochem. Pharmacol. 2000, 60, 457–470.
[CrossRef]
J. Fungi 2017, 3, 11 21 of 30
84. Wilson, D.; Thewes, S.; Zakikhany, K.; Fradin, C.; Albrecht, A.; Almeida, R.; Brunke, S.; Grosse, K.;
Martin, R.; Mayer, F.; et al. Identifying infection-associated genes of Candida albicans in the postgenomic era.
FEMS Yeast Res. 2009, 9, 688–700. [CrossRef] [PubMed]
85. Brunke, S.; Seider, K.; Almeida, R.; Heyken, A.; Fleck, C.; Brock, M.; Barz, D.; Rupp, S.; Hube, B.
Candida glabrata tryptophan-based pigment production via the Ehrlich pathway. Mol. Microbiol. 2010,
76, 25–47. [CrossRef] [PubMed]
86. Tscherner, M.; Schwarzmüller, T.; Kuchler, K. Pathogenesis and Antifungal Drug Resistance of the Human
Fungal Pathogen Candida glabrata. Pharmaceuticals 2011, 4, 169–186. [CrossRef]
87. Henry, K.; Nickels, J.; Edlind, T. Upregulation of ERG genes in Candida species by azoles and other sterol
biosynthesis inhibitors. Antimicrob. Agents Chemother. 2000, 44, 2693–2700. [CrossRef] [PubMed]
88. Stead, D.A.; Walker, J.; Holcombe, L.; Gibbs, S.R.S.; Yin, Z.; Selway, L.; Butler, G.; Brown, A.J.P.; Haynes, K.
Impact of the transcriptional regulator, ACE2, on the Candida glabrata secretome. Proteomics 2010, 10, 212–223.
[CrossRef] [PubMed]
89. Calcagno, A.; Bignell, E.; Warn, P.; Jones, M.; Denning, D.; Muhlschlegel, F.; Rogers, T.; Haynes, K.
C. glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation.
Mol. Microbiol. 2003, 50, 1309–1318. [CrossRef] [PubMed]
90. Kanafani, Z.A.; Perfect, J.R. Resistance to antifungal agents: mechanisms and clinical impact.
Clin. Infect. Dis. 2008, 46, 120–128. [CrossRef] [PubMed]
91. Ferrari, S.; Sanguinetti, M.; Torelli, R.; Posteraro, B.; Sanglard, D. Contribution of CgPDR1-regulated genes in
enhanced virulence of azole-resistant Candida glabrata. PLoS ONE 2011, 6, e17589. [CrossRef] [PubMed]
92. Ferrari, S.; Sanguinetti, M.; De Bernardis, F.; Torelli, R.; Posteraro, B.; Vandeputte, P.; Sanglard, D. Loss of
mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in
mice. Antimicrob. Agents Chemother. 2011, 55, 1852–1860. [CrossRef] [PubMed]
93. Noble, J.A.; Tsai, H.F.; Suffis, S.D.; Su, Q.; Myers, T.G.; Bennett, J.E. STB5 is a negative regulator of azole
resistance in Candida glabrata. Antimicrob. Agents Chemother. 2013, 57, 959–967. [CrossRef] [PubMed]
94. Vermitsky, J.; Edlind, T.D. Azole Resistance in Candida glabrata: Coordinate upregulation of multidrug
transporters and evidence for a PDR1-like transcription factor. Antimicrob. Agents Chemother. 2004, 48,
3773–3781. [CrossRef] [PubMed]
95. Vale-Silva, L.; Ischer, F.; Leibundgut-Landmann, S.; Sanglard, D. Gain-of-function mutations in PDR1, a
regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect. Immun.
2013, 81, 1709–1720. [CrossRef] [PubMed]
96. Paul, S.; Schmidt, J.A.; Moye-Rowley, W.S. Regulation of the CGPDR1 transcription factor from the pathogen
Candida glabrata. Eukaryot. Cell 2011, 10, 187–197. [CrossRef] [PubMed]
97. Farahyar, S.; Zaini, F.; Kordbacheh, P.; Rezaie, S.; Falahati, M.; Safara, M. Expression of efflux pumps and
fatty acid activator one genes in azole resistant Candida glabrata isolated from immunocompromised patients.
Acta Med. Iran. 2015, 54, 458–464.
98. Kaur, R.; Castan, I.; Cormack, B.P. Functional genomic analysis of fluconazole susceptibility in the pathogenic
yeast Candida glabrata: Roles of calcium signaling and mitochondria. Antimicrob. Agents Chemother. 2004, 48,
1600–1613. [CrossRef] [PubMed]
99. Miyazaki, T.; Yamauchi, S.; Inamine, T.; Nagayoshi, Y.; Saijo, T.; Izumikawa, K.; Seki, M.; Kakeya, H.;
Yamamoto, Y.; Yanagihara, K.; et al. Roles of calcineurin and Crz1 in antifungal susceptibility and virulence
of Candida glabrata. Antimicrob. Agents Chemother. 2010, 54, 1639–1643. [CrossRef] [PubMed]
100. Kaur, R.; Ma, B.; Cormack, B.P. A family of glycosylphosphatidylinositol-linked aspartyl proteases is required
for virulence of Candida glabrata. Proc. Natl. Acad. Sci. USA. 2007, 104, 7628–7633. [CrossRef] [PubMed]
101. Akins, R.A. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol.
2005, 43, 285–318. [CrossRef] [PubMed]
102. Marichal, P.; Koymans, L.; Willemsens, S.; Bellens, D.; Verhasselt, P.; Luyten, W.; Borgers, M.; Ramaekers, F.C.;
Odds, F.C.; Bossche, H.V. Contribution of mutations in the cytochrome P450 14-α-demethylase
(Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999, 145, 2701–2713. [CrossRef]
103. Morio, F.; Pagniez, F.; Lacroix, C.; Miegeville, M.; Le Pape, P. Amino acid substitutions in the Candida albicans
sterol D5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired
virulence. J. Antimicrob. Chemother. 2012, 67, 2131–2138. [CrossRef] [PubMed]
J. Fungi 2017, 3, 11 22 of 30
104. Szweda, P.; Gucwa, K.; Romanowska, E.; Dzierzanowska-Fangrat, K.; Naumiuk, L.; Brillowska-Dabrowska, A.;
Wojciechowska-Koszko, I.; Milewski, S. Mechanisms of azole resistance among clinical isolates of
Candida glabrata in Poland. J. Med. Microbiol. 2015, 64, 610–619. [CrossRef]
105. Aramburu, J.; Rao, A.; Klee, C.B. Calcineurin: from structure to function. Curr. Top. Cell. Regul. 2000, 36,
237–295. [PubMed]
106. Onyewu, C.; Blankenship, J.R.; Del Poeta, M.; Heitman, J. Ergosterol biosynthesis inhibitors become
fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida
krusei. Antimicrob. Agents Chemother. 2003, 47, 956–964. [CrossRef] [PubMed]
107. Cruz, M.C.; Goldstein, A.L.; Blankenship, J.R.; Del Poeta, M.; Davis, D.; Cardenas, M.E.; Perfect, J.R.;
McCusker, J.H.; Heitman, J. Calcineurin is essential for survival during membrane stress in Candida albicans.
EMBO J. 2002, 21, 546–559. [CrossRef] [PubMed]
108. Chen, K.H.; Miyazaki, T.; Tsai, H.F.; Bennett, J.E. The bZip transcription factor CGAP1P is involved in
multidrug resistance and required for activation of multidrug transporter gene CgFLR1 in Candida glabrata.
Gene 2007, 386, 63–72. [CrossRef] [PubMed]
109. Farahyar, S.; Zaini, F.; Kordbacheh, P.; Rezaie, S.; Safara, M.; Raoofian, R.; Heidari, M. Overexpression
of Aldo-Keto-reductase in Azole-resistant clinical isolates of Candida glabrata determined by cDNA-AFLP.
Daru J. Pharm. Sci. 2013, 21, 1. [CrossRef] [PubMed]
110. Taff, H.T.; Nett, J.E.; Zarnowski, R.; Ross, K.M.; Sanchez, H.; Cain, M.T.; Hamaker, J.; Mitchell, A.P.;
Andes, D.R. A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance.
PLoS Pathog. 2012, 8, e1002848. [CrossRef] [PubMed]
111. Berenguer, J.; Rodriguez-Tudela, J.; Richard, C.; Alvarez, M.; Sanz, M.; Gaztelurrutia, L.; Ayats, J.;
Martinez-Suarez, J. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain
and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine 1997, 76, 256–265.
[CrossRef]
112. Boutati, E.; Anaissie, E. Fusarium, a significant emerging pathogen in patients with hematologic malignancy:
ten years’ experience at a cancer center and implications for management. Blood 1997, 90, 999–1008. [PubMed]
113. Tritz, D.; Woods, G. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts.
Clin. Infect. Dis. 1993, 16, 118–122. [CrossRef] [PubMed]
114. Rex, J.H.J.; Walsh, T.J.; Sobel, J.D.J.; Filler, S.G.; Pappas, P.G.; Dismukes, W.E.; Edwards, J.E. Practice guidelines
for the treatment of candidiasis. Clin. Infect. Dis. 2000, 30, 662–678. [CrossRef] [PubMed]
115. Vandeputte, P.; Tronchin, G.; Larcher, G.; Ernoult, E.; Bergès, T.; Chabasse, D.; Bouchara, J.-P. A nonsense
mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata.
Antimicrob. Agents Chemother. 2008, 52, 3701–3709. [CrossRef]
116. Vandeputte, P.; Tronchin, G.; Bergès, T.; Hennequin, C.; Chabasse, D.; Bouchara, J.P. Reduced susceptibility
to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata
with pseudohyphal growth. Antimicrob. Agents Chemother. 2007, 51, 982–990. [CrossRef] [PubMed]
117. Shields, R.K.; Nguyen, M.H.; Press, E.G.; Kwa, A.L.; Cheng, S.; Du, C.; Clancy, C.J. The presence of an
FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among
patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 2012, 56, 4862–4869.
[CrossRef] [PubMed]
118. Beyda, N.D.; Lewis, R.E.; Garey, K.W. Echinocandin resistance in Candida species: mechanisms of reduced
susceptibility and therapeutic approaches. Ann. Pharmacother. 2012, 46, 1086–1096. [CrossRef] [PubMed]
119. Walker, L.A.; Gow, N.A.; Munro, C.A. Fungal echinocandin resistance. Fungal Genet. Biol. 2010, 47, 117–126.
[CrossRef] [PubMed]
120. Barchiesi, F.; Barchiesi, F.; Spreghini, E.; Tomas- setti, S.; Della Vittoria, A.; Arzeni, D.; Manso, E.; Scalise, G.
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother.
2006, 2719–2727. [CrossRef] [PubMed]
121. Garcia-Effron, G.; Katiyar, S.K.; Park, S.; Edlind, T.D.; Perlin, D.S. A naturally occurring proline-to-alanine
amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts
for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 2008, 52, 2305–2312. [CrossRef] [PubMed]
122. Vai, M.; Orlandi, I.; Cavadini, P.; Alberghina, L.; Popolo, L. Candida albicans homologue of GGP1/GAS1 gene
is functional in Saccharomyces cerevisiae and contains the determinants for glycosylphosphatidylinositol
attachment. Yeast 1996, 12, 361–368. [CrossRef]
J. Fungi 2017, 3, 11 23 of 30
123. Garcia-Effron, G.; Lee, S.; Park, S.; Cleary, J.D.; Perlin, D.S. Effect of Candida glabrata FKS1 and FKS2 mutations
on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility
breakpoint. Antimicrob. Agents Chemother. 2009, 53, 3690–3699. [CrossRef] [PubMed]
124. Alexander, B.D.; Johnson, M.D.; Pfeiffer, C.D.; Jimenez-Ortigosa, C.; Catania, J.; Booker, R.; Castanheira, M.;
Messer, S.A.; Perlin, D.S.; Pfaller, M.A. Increasing echinocandin resistance in Candida glabrata: clinical failure
correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis.
2013, 56, 1724–1732. [CrossRef] [PubMed]
125. Thompson, G.R.; Wiederhold, N.P.; Vallor, A.C.; Villareal, N.C.; Lewis, J.S.; Patterson, T.F. Development of
caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata
infection. Antimicrob. Agents Chemother. 2008, 52, 3783–3785. [CrossRef] [PubMed]
126. Arendrup, M.; Perlin, D.; Jensen, R.; Howard, S.; Goodwin, J.; Hopec, W. Differential in vivo activities
of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FSK
resistance mutations. Antimicrob. Agents Chemother. 2012, 2435–2442. [CrossRef] [PubMed]
127. Stevens, D.A.; White, T.C.; Perlin, D.S.; Selitrennikoff, C.P. Studies of the paradoxical effect of caspofungin at
high drug concentrations. Diagn. Microbiol. Infect. Dis. 2005, 51, 173–178. [CrossRef] [PubMed]
128. Chamilos, G.; Lewis, R.E.; Albert, N.; Kontoyiannis, D.P. Paradoxical effect of echinocandins across
candida species In vitro: Evidence for echinocandin-specific and candida species-related differences.
Antimicrob. Agents Chemother. 2007, 51, 2257–2259. [CrossRef] [PubMed]
129. Balashov, S.V.; Park, S.; Perlin, D.S. Assessing resistance to the echinocandin antifungal drug caspofungin
in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 2006, 50, 2058–2063.
[CrossRef] [PubMed]
130. Ramage, G.; Rajendran, R.; Sherry, L.; Williams, C. Fungal biofilm resistance. Int. J. Microbiol. 2012, 2012,
528521. [CrossRef] [PubMed]
131. Mathé, L.; Van Dijck, P. Recent insights into Candida albicans biofilm resistance mechanisms. Curr. Genet.
2013, 59, 251–264. [CrossRef] [PubMed]
132. Taff, H.T.; Mitchell, K.F.; Edward, J.A.; Andes, D.R. Mechanisms of Candida biofilm drug resistance.
Futur. Microbiol. 2013, 8, 1325–1337. [CrossRef] [PubMed]
133. Fox, E.; Singh-babak, S.; Hartooni, N.; Nobile, C. Biofilms and antifungal resistance. In Antifungals from
Genomics to Resistance and the Development of Novel Agents; Coste, A., Vandeputte, P., Eds.; Caister Academic
Press: Poole, UK, 2015; pp. 71–90.
134. Anderson, J.B. Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness. Nat. Rev. Microbiol.
2005, 3, 547–556. [CrossRef] [PubMed]
135. Jabra-Rizk, M.A.; Falkler, W.A.; Meiller, T.F. Fungal biofilms and drug resistance. Emerg. Infect. Dis. 2004, 10,
14–19. [CrossRef] [PubMed]
136. Nett, J.; Lepak, A.; Marchillo, K.; Andes, D. Time course global gene expression analysis of an in vivo
Candida biofilm. J. Infect. Dis. 2009, 200, 307–313. [CrossRef] [PubMed]
137. Ramage, G.; Vandewalle, K.; Wickes, B.; López-Ribot, J. Characteristics of biofilm formation by
Candida albicans. Rev. Iberoam. Micol. 2001, 18, 163–170. [PubMed]
138. Mukherjee, P.K.; Chandra, J.; Kuhn, D.M.; Ghannoum, M.A. Mechanism of fluconazole resistance in
Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 2003, 71,
4333–4340. [CrossRef] [PubMed]
139. Andes, D.; Nett, J.; Oschel, P.; Albrecht, R.; Marchillo, K.; Pitula, A. Development and characterization of an
in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 2004, 72, 6023–6031. [CrossRef]
[PubMed]
140. Mateus, C.; Crow, S.A.; Ahearn, D.G. Adherence of Candida albicans to silicone induces immediate enhanced
tolerance to fluconazole. Antimicrob. Agents Chemother. 2004, 48, 3358–3366. [CrossRef] [PubMed]
141. Nobile, C.J.; Fox, E.P.; Nett, J.E.; Sorrells, T.R.; Mitrovich, Q.M.; Hernday, A.D.; Tuch, B.B.; Andes, D.R.;
Johnson, A.D. A recently evolved transcriptional network controls biofilm development in Candida albicans.
Cell 2012, 148, 126–138. [CrossRef] [PubMed]
142. Ramage, G.; Bachmann, S.; Patterson, T.F.; Wickes, B.L.; López-Ribot, J.L. Investigation of multidrug efflux
pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 2002, 49,
973–980. [CrossRef] [PubMed]
J. Fungi 2017, 3, 11 24 of 30
143. Yeater, K.; Chandra, J.; Cheng, G.; Mukherjee, P.; Zhao, X.; Rodriguez- Zas, S.; Kwast, K.; Ghannoum, M.;
Hoyer, L. Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology
2007, 2373–2385. [CrossRef] [PubMed]
144. Nguyen, M.H.; Yu, C.Y. Influence of incubation time, inoculum size, and glucose concentrations
on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole.
J. Clin. Microbiol. 1999, 37, 141–145. [PubMed]
145. European Committee on Antimicrobial Susceptibility Testing—Antifungal agents, Breakpoint tables for
interpretation of MICs, Version 8.0, valid from 2015-11-16. Available online: http://www.eucast.org/clinical_
breakpoints/ (accessed on 1 December 2016).
146. National Committee for Clinical Laboratory Standards. 1997. Available online: http://clsi.org/ (accessed on
1 December 2016).
147. Perumal, P.; Mekala, S.; Chaffin, W.L. Role for cell density in antifungal drug resistance in Candida albicans
biofilms. Antimicrob. Agents Chemother. 2007, 51, 2454–2463. [CrossRef] [PubMed]
148. Hornby, J.; Jensen, E.; Lisec, A.; Tasto, J.; Jahnke, B.; Shoemaker, R.; Dussault, P.; Nickerson, K. Quorum
sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Env. Microbiol. 2001, 67,
2982–2992. [CrossRef] [PubMed]
149. Al-fattani, M.A.; Douglas, L.J. Penetration of candida biofilms by antifungal agents. Antimicrob. Agents
Chemother. 2004, 48, 3291–3297. [CrossRef] [PubMed]
150. Al-Fattani, M.A.; Douglas, L.J. Biofilm matrix of Candida albicans and Candida tropicalis: Chemical composition
and role in drug resistance. J. Med. Microbiol. 2006, 55, 999–1008. [CrossRef] [PubMed]
151. Lal, P.; Sharma, D.; Pruthi, P.; Pruthi, V. Exopolysaccharide analysis of biofilm-forming Candida albicans.
J. Appl. Microbiol. 2010, 109, 128–136. [CrossRef] [PubMed]
152. Martins, M.; Uppuluri, P.; Thomas, D.P.; Cleary, I.A.; Henriques, M.; Lopez-Ribot, J.L.; Oliveira, R. Presence
of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia
2010, 169, 323–331. [CrossRef] [PubMed]
153. Martins, M.; Henriques, M.; Lopez-Ribot, J.L.; Oliveira, R. Addition of DNase improves the in vitro activity
of antifungal drugs against Candida albicans biofilms. Mycoses 2012, 55, 80–85. [CrossRef] [PubMed]
154. Kojic, E.M.; Darouiche, R.O. Candida infections of medical devices. Clin. Microbiol. Rev. 2004, 17, 255–267.
[CrossRef] [PubMed]
155. Mitchell, K.F.; Taff, H.T.; Cuevas, M.A.; Reinicke, E.L.; Sanchez, H.; Andes, D.R. Role of matrix β-1,3-glucan
in antifungal resistance of non-albicans Candida biofilms. Antimicrob. Agents Chemother. 2013, 57, 1918–1920.
[CrossRef] [PubMed]
156. Vediyappan, G.; Rossignol, T.; D’Enfert, C. Interaction of Candida albicans biofilms with antifungals:
Transcriptional response and binding of antifungals to β-glucans. Antimicrob. Agents Chemother. 2010.
[CrossRef] [PubMed]
157. Bandara, H.M.H.N.; Lam, O.L.T.; Watt, R.M.; Jin, L.J.; Samaranayake, L.P. Bacterial lipopolysaccharides
variably modulate in vitro biofilm formation of Candida species. J. Med. Microbiol. 2010, 59, 1225–1234.
[CrossRef] [PubMed]
158. Halliwell, S.C.; Smith, M.C.A.; Muston, P.; Holland, S.L.; Avery, S.V. Heterogeneous expression of the
virulence-related adhesin EPA1 between individual cells and strains of the pathogen Candida glabrata.
Eukaryot. Cell 2012, 11, 141–150. [CrossRef] [PubMed]
159. Chandra, J.; Kuhn, D.; Mukherjee, P.; Hoyer, L.; McCormick, T.; Ghannoum, M. Biofilm formation by the
fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 2001, 183,
5385–5394. [CrossRef] [PubMed]
160. Baillie, G.S.; Douglas, L.J. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents.
Antimicrob. Agents Chemother. 1998, 42, 1900–1905. [PubMed]
161. Baillie, G.S.; Douglas, L.J. Iron-limited biofilms of Candida albicans and their susceptibility to amphotericin B.
Antimicrob. Agents Chemother. 1998, 42, 2146–2149. [PubMed]
162. Cannon, R.; Lamping, E.; Holmes, A. Candida albicans drug resistance—Another way to cope with stress.
Microbiol 2007, 153, 3211–3217. [CrossRef] [PubMed]
163. Seneviratne, C.J.; Wang, Y.; Jin, L.; Abiko, Y.; Samaranayake, L.P. Proteomics of drug resistance in
Candida glabrata biofilms. Proteomics 2010, 10, 1444–1454. [CrossRef] [PubMed]
J. Fungi 2017, 3, 11 25 of 30
164. LaFleur, M.D.; Kumamoto, C.A.; Lewis, K. Candida albicans biofilms produce antifungal-tolerant persister
cells. Antimicrob. Agents Chemother. 2006, 50, 3839–3846. [CrossRef] [PubMed]
165. Khot, P.D.; Suci, P.A.; Miller, R.L.; Nelson, R.D.; Tyler, B.J. A small subpopulation of blastospores in
Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of
ergosterol and β-1,6-glucan pathway genes. Antimicrob. Agents Chemother. 2006, 50, 3708–3716. [CrossRef]
[PubMed]
166. Al-Dhaheri, R.S.; Douglas, L.J. Absence of amphotericin B-tolerant persister cells in biofilms of some Candida
species. Antimicrob. Agents Chemother. 2008, 52, 1884–1887. [CrossRef] [PubMed]
167. Bojsen, R.; Regenberg, B.; Gresham, D.; Folkesson, A. A common mechanism involving the TORC1 pathway
can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations.
Sci. Rep. 2016, 6, 21874. [CrossRef] [PubMed]
168. Wang, E.; Farmakiotis, D.; Yang, D.; McCue, D.A.; Kantarjian, H.M.; Kontoyiannis, D.P.; Mathisen, M.S.
The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to
caspofungin and multidrug resistance are associated with increased mortality. J. Antimicrob. Chemother. 2015.
[CrossRef] [PubMed]
169. Pfaller, M.A.; Castanheira, M.; Lockhart, S.R.; Ahlquist, A.M.; Messer, S.A.; Jones, R.N. Frequency of
decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates
of Candida glabrata. J. Clin. Microbiol. 2012, 50, 1199–1203. [CrossRef] [PubMed]
170. Cleveland, A.A.; Harrison, L.H.; Farley, M.M.; Hollick, R.; Stein, B.; Chiller, T.M.; Lockhart, S.R.; Park, B.J.
Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US
metropolitan areas, 2008-2013: Results from population-based surveillance. PLoS ONE 2015, 10, e0120452.
[CrossRef] [PubMed]
171. Razzaghi-Abyaneh, M.; Sadeghi, G.; Zeinali, E.; Alirezaee, M.; Shams-Ghahfarokhi, M.; Amani, A.;
Mirahmadi, R.; Tolouei, R. Species distribution and antifungal susceptibility of Candida spp. isolated
from superficial Candidiasis in outpatients in Iran. J. Mycol. Med. 2014, 24, e43–e50. [CrossRef] [PubMed]
172. Sanguinetti, M.; Posteraro, B.; Lass-Florl, C. Antifungal drug resistance among Candida species: Mechanisms
and clinical impact. Mycoses 2015, 2, 2–13. [CrossRef] [PubMed]
173. Farmakiotis, D.; Tarrand, J.J.; Kontoyiannis, D.P. Drug-resistant Candida glabrata infection in cancer patients.
Emerg. Infect. Dis. 2014, 20, 1833–1840. [CrossRef] [PubMed]
174. Mohamadi, J.; Motaghi, M.; Panahi, J.; Havasian, M.R.; Delpisheh, A.; Azizian, M.; Pakzad, I. Anti-fungal
resistance in candida isolated from oral and diaper rash Candidiasis in neonates. Bioinformation 2014, 10,
667–670. [CrossRef] [PubMed]
175. Nieto, M.C.; Tellería, O.; Cisterna, R. Sentinel surveillance of invasive candidiasis in Spain: Epidemiology
and antifungal susceptibility. Diagn. Microbiol. Infect. Dis. 2015, 81, 34–40. [CrossRef] [PubMed]
176. Pfaller, M.A.; Rhomberg, P.R.; Messer, S.A.; Jones, R.N.; Castanheira, M. Isavuconazole, micafungin,
and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic
fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical
breakpoints and proposed epidemiological cutoff values. Diagn. Microbiol. Infect. Dis. 2015, 82, 303–313.
[CrossRef] [PubMed]
177. Schmalreck, A.F.; Willinger, B.; Haase, G.; Blum, G.; Lass-Flörl, C.; Fegeler, W.; Becker, K. Antifungal
Susceptibility Testing-AFST Study Group Species and susceptibility distribution of 1062 clinical yeast isolates
to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses 2012, 55,
e124–e137. [CrossRef] [PubMed]
178. Shi, X.Y.; Yang, Y.P.; Zhang, Y.; Li, W.; Wang, J.D.; Huang, W.M.; Fan, Y.M. Molecular identification
and antifungal susceptibility of 186 Candida isolates from vulvovaginal Candidiasis in Southern China.
J. Med. Microbiol. 2015, 64, 390–393. [CrossRef] [PubMed]
179. Zarei Mahmoudabadi, A.; Rezaei-Matehkolaei, A.; Ghanavati, F. The Susceptibility Patterns of Candida
Species Isolated From Urine Samples to Posaconazole and Caspofungin. Jundishapur J. Microbiol. 2015, 8.
[CrossRef] [PubMed]
180. Posteraro, B.; Spanu, T.; Fiori, B.; De Maio, F.; De Carolis, E.; Giaquinto, A.; Prete, V.; De Angelis, G.; Torelli, R.;
D’Inzeo, T.; et al. Antifungal susceptibility profiles of bloodstream yeast isolates by sensititre yeastone over
nine years at a large Italian teaching hospital. Antimicrob. Agents Chemother. 2015, 59, 3944–3955. [CrossRef]
[PubMed]
J. Fungi 2017, 3, 11 26 of 30
181. Czaika, V.; Nenoff, P.; Glöckner, A.; Becker, K.; Fegeler, W.; Schmalreck, A.F. Detection of azole susceptibility
patterns in clinical yeast strains isolated from 1998 to 2008. New Microbiol. 2014, 37, 465–494. [PubMed]
182. Pfaller, M.A.; Messer, S.A.; Boyken, L.; Tendolkar, S.; Hollis, R.J.; Diekema, D.J. Geographic variation in
the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents:
A global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
J. Clin. Microbiol. 2004, 42, 3142–3146. [CrossRef] [PubMed]
183. Gopinathan, S.; Janagond, A.B.; Agatha, D.; P R, T. Detection of FUR1 Gene in 5-flucytosine resistant candida
isolates in vaginal candidiasis patients. J. Clin. Diagn. Res. 2013, 7, 2452–2455. [CrossRef] [PubMed]
184. Haddadi, P.; Zareifar, S.; Badiee, P.; Alborzi, A.; Mokhtari, M.; Zomorodian, K.; Pakshir, K.; Jafarian, H.
Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. Jundishapur J.
Microbiol. 2014, 7, e11858. [CrossRef] [PubMed]
185. Ibrahim, N.H.; Melake, N.A.; Somily, A.M.; Zakaria, A.S.; Baddour, M.M.; Mahmoud, A.Z. The effect of
antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida
species induced biofilms. Saudi Pharm. J. SPJ Off. Publ. Saudi Pharm. Soc. 2015, 23, 55–66. [CrossRef] [PubMed]
186. Andrade-Silva, L.; Ferreira-Paim, K.; Mora, D.J.; Da Silva, P.R.; Andrade, A.A.; Araujo, N.E.; Pedrosa, A.L.;
Silva-Vergara, M.L. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans
and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil. Med. Mycol. 2013, 51, 635–640. [CrossRef] [PubMed]
187. Oxman, D.A.; Chow, J.K.; Frendl, G.; Hadley, S.; Hershkovitz, S.; Ireland, P.; McDermott, L.A.; Tsai, K.;
Marty, F.M.; Kontoyiannis, D.P.; Golan, Y. Candidaemia associated with decreased in vitro fluconazole
susceptibility: is Candida speciation predictive of the susceptibility pattern? J. Antimicrob. Chemother. 2010,
65, 1460–1465. [CrossRef] [PubMed]
188. Pfaller, M.A.; Messer, S.A.; Jones, R.N.; Castanheira, M. Antifungal susceptibilities of Candida, Cryptococcus
neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: Data from the SENTRY
antifungal surveillance program (2010–2012). J. Antibiot. 2015, 68, 556–561. [CrossRef] [PubMed]
189. Lee, C.H.; Chang, T.Y.; Liu, J.W.; Chen, F.J.; Chien, C.C.; Tang, Y.F.; Lu, C.H. Correlation of anti-fungal
susceptibility with clinical outcomes in patients with cryptococcal meningitis. BMC Infect. Dis. 2012, 12, 361.
[CrossRef] [PubMed]
190. Matos, C.S.; de Souza Andrade, A.; Oliveira, N.S.; Barros, T.F. Microbiological characteristics of clinical
isolates of Cryptococcus spp. in Bahia, Brazil: Molecular types and antifungal susceptibilities. Eur. J. Clin.
Microbiol. Infect. Dis. 2012, 31, 1647–1652. [CrossRef] [PubMed]
191. Asadzadeh, M.; Al-Sweih, N.A.; Ahmad, S.; Khan, Z.U. Antifungal susceptibility of clinical
Candida parapsilosis isolates in Kuwait. Mycoses 2008, 51, 318–323. [CrossRef]
192. Hegazi, M.; Abdelkader, A.; Zaki, M.; El-Deek, B. Characteristics and risk factors of candidemia in pediatric
intensive care unit of a tertiary care children’s hospital in Egypt. J. Infect. Dev. Ctries. 2014, 8, 624–634.
[CrossRef] [PubMed]
193. Zaoutis, T.E.; Foraker, E.; McGowan, K.L.; Mortensen, J.; Campos, J.; Walsh, T.J.; Klein, J.D. Antifungal
susceptibility of Candida spp. isolated from pediatric patients: A survey of 4 children’s hospitals.
Diagn. Microbiol. Infect. Dis. 2005, 52, 295–298. [CrossRef] [PubMed]
194. Krogh-Madsen, M.; Arendrup, M.C.; Heslet, L.; Knudsen, J.D. Amphotericin B and Ca- spofungin resistance
in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 2006, 42, 938–944. [CrossRef]
[PubMed]
195. Martel, C.M.; Parker, J.E.; Bader, O.; Weig, M.; Gross, U.; Warrilow, A.G.S.; Rolley, N.; Kelly, D.E.; Kelly, S.L.
Identification and characterization of four azole-resistant Erg3 mutants of Candida albicans. Antimicrob. Agents
Chemother. 2010, 54, 4527–4533. [CrossRef] [PubMed]
196. Eddouzi, J.; Parker, J.E.; Vale-Silva, L.A.; Coste, A.; Ischer, F.; Kelly, S.; Manai, M.; Sanglard, D.
Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
Antimicrob. Agents Chemother. 2013, 3182–3193. [CrossRef] [PubMed]
197. Forastiero, A.; Mesa-Arango, A.C.; Alastruey-Izquierdo, A.; Alcazar-Fuoli, L.; Bernal-Martinez, L.; Pelaez, T.;
Lopez, J.F.; Grimalt, J.O.; Gomez- Lopez, A.; Cuesta, I.; Zaragoza, O.; Mellado, E. Candida tropicalis antifungal
cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob. Agents Chemother. 2013,
57, 4769–4781. [CrossRef] [PubMed]
J. Fungi 2017, 3, 11 27 of 30
198. Costa, C.; Pais, P.; Teixeira, M.C. Multidrug resistance in pathogenic yeasts: Emphasis on the role of ABC and
MFS multidrug transporters. In The Battle Against Microbial Pathogens: Basic Science, Technological Advances
and Educational Programs; Formatex: Badajoz, Spain, 2015; pp. 947–954.
199. Sanglard, D.; Ischer, F.; Bille, J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition
of resistance to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 2001, 45, 1174–1183.
[CrossRef] [PubMed]
200. Torelli, R.; Posteraro, B.; Ferrari, S.; La Sorda, M.; Fadda, G.; Sanglard, D.; Sanguinetti, M. The ATP-binding
cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of
Candida glabrata. Mol. Microbiol. 2008, 68, 186–201. [CrossRef] [PubMed]
201. Healey, K.R.; Zhao, Y.; Perez, W.B.; Lockhart, S.R.; Sobel, J.D.; Farmakiotis, D.; Kontoyiannis, D.P.;
Sanglard, D.; Taj-Aldeen, S.J.; Alexander, B.D.; et al. Prevalent mutator genotype identified in fungal
pathogen Candida glabrata promotes multi-drug resistance. Nat. Commun. 2016, 7, 11128. [CrossRef] [PubMed]
202. Thakur, J.K.; Arthanari, H.; Yang, F.; Pan, S.J.; Fan, X.; Breger, J.; Frueh, D.P.; Gulshan, K.; Li, D.K.;
Mylonakis, E.; et al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature
2008, 452, 604–609. [CrossRef] [PubMed]
203. Yang, F.; Vought, B.W.; Satterlee, J.S.; Walker, A.K.; Sun, Z.-Y.J.; Watts, J.L.; DeBeaumont, R.; Mako Saito, R.;
Hyberts, S.G.; Yang, S.; Macol, C.; et al. An ARC/Mediator subunit required for SREBP control of cholesterol
and lipid homeostasis. Nature 2006, 442, 700–704. [CrossRef] [PubMed]
204. Nishikawa, J.L.; Boeszoermenyi, A.; Vale-Silva, L.A.; Torelli, R.; Posteraro, B.; Sohn, Y.J.; Ji, F.;
Gelev, V.; Sanglard, D.; Sanguinetti, M.; et al. Inhibiting fungal multidrug resistance by disrupting an
activator-Mediator interaction. Nature 2016, 530, 485–489. [CrossRef] [PubMed]
205. Paul, S.; Moye-Rowley, W.S. Multidrug resistance in fungi: Regulation of transporter-encoding gene
expression. Front. Physiol. 2014, 5 APR, 143. [CrossRef] [PubMed]
206. Orta-Zavalza, E.; Guerrero-Serrano, G.; Gutiérrez-Escobedo, G.; Cañas-Villamar, I.; Juárez-Cepeda, J.;
Castaño, I.; De Las Peñas, A. Local silencing controls the oxidative stress response and the multidrug
resistance in Candida glabrata. Mol. Microbiol. 2013, 88, 1135–1148. [CrossRef] [PubMed]
207. Costa, C.; Pires, C.; Cabrito, T.R.; Renaudin, A.; Ohno, M.; Chibana, H.; Sá-Correia, I.; Teixeira, M.C.
Candida glabrata drug:H+ antiporter CgQdr2 confers imidazole drug resistance, being activated by
transcription factor CgPdr1. Antimicrob. Agents Chemother. 2013, 57, 3159–3167. [CrossRef] [PubMed]
208. Costa, C.; Nunes, J.; Henriques, A.; Mira, N.P.; Nakayama, H.; Chibana, H.; Teixeira, M.C. Candida glabrata
drug:H+ antiporter CgTpo3 (ORF CAGL0I10384g): role in azole drug resistance and polyamine homeostasis.
J. Antimicrob. Chemother. 2014, 69, 1767–1776. [CrossRef] [PubMed]
209. Costa, C.; Henriques, A.; Pires, C.; Nunes, J.; Ohno, M.; Chibana, H.; Sá-Correia, I.; Teixeira, M.C. The dual
role of Candida glabrata drug:H+ antiporter CgAqr1 (ORF CAGL0J09944g) in antifungal drug and acetic acid
resistance. Front. Microbiol. 2013, 4, 170. [CrossRef] [PubMed]
210. Hull, C.M.; Parker, J.E.; Bader, O.; Weig, M.; Gross, U.; Warrilow, A.G.S.; Kelly, D.E.; Kelly, S.L. Facultative
sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in
ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob. Agents Chemother. 2012, 56,
4223–4232. [CrossRef] [PubMed]
211. Brun, S.; Bergès, T.; Poupard, P.; Vauzelle-Moreau, C.; Renier, G.; Chabasse, D.; Bouchara, J.-P. Mechanisms
of azole resistance in petite mutants of Candida glabrata. Antimicrob. Agents Chemother. 2004, 48, 1788–1796.
[CrossRef] [PubMed]
212. Ferrari, S.; Ischer, F.; Calabrese, D.; Posteraro, B.; Sanguinetti, M.; Fadda, G.; Rohde, B.; Bauser, C.; Bader, O.;
Sanglard, D. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance
but also enhance virulence. PLoS Pathog. 2009, 5, e1000268. [CrossRef] [PubMed]
213. Mansfield, B.E.; Oltean, H.N.; Oliver, B.G.; Hoot, S.J.; Leyde, S.E.; Hedstrom, L.; White, T.C.; BE, M. Azole
drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog. 2010,
6, e1001126. [CrossRef] [PubMed]
214. Miranda, I.M.; Silva, R.M.; Estevinho, M.; Pina-vaz, C. Environmental azole fungicide, prochloraz,
can induce cross-resistance to medical triazoles in Candida glabrata. FEMS Yeast Res. 2014, 1–5.
215. Helmerhorst, E.; Venuleo, C.; Sanglard, D.; Oppenheim, F. Roles of cellular respiration, CgCDR1, and
CgCDR2 in Candida glabrata resistance to histatin. Antimicrob. Agents Chemother. 2006, 1100–1103. [CrossRef]
[PubMed]
J. Fungi 2017, 3, 11 28 of 30
216. Edgerton, M.; Koshlukova, S. Salivary histatin 5 and its similarities to the other antimicrobial proteins in
human saliva. Adv. Dent. Res. 2000, 14, 16–21. [CrossRef] [PubMed]
217. Helmerhorst, E.; Hancock, R.; Devine, D.; Oppenheim, F. The antifungal mechanisms of antimicrobial
proteins. In Mammalian Antimicrobial Proteins; Hancock, R., Devine, D., Eds.; Cambridge University Press:
Cambridge, UK, 2004; pp. 245–277.
218. Oppenheim, F. Salivary histidine-rich proteins. In Human Saliva: Clinical Chemistry and Microbiology;
Tenovuo, J., Ed.; CRC Press: Boca Raton, FL, USA, 1989; pp. 151–160.
219. Oppenheim, F.; Xu, T.; McMillian, F.; Levitz, S.; Diamond, R.; Offner, G.; Troxler, R. Histatins, a novel family
of histidinerich proteins in human parotid secretion. Isolation, characterization, primary structure, and
fungistatic effects on Candida albicans. J. Biol. Chem. 1988, 263, 7472–7477. [PubMed]
220. Tsai, H.; Bobek, L. Human salivary histatins: promising antifungal therapeutic agents. Crit. Rev. Oral
Biol. Med. 1998, 9, 480–497. [CrossRef] [PubMed]
221. van Urk, H.; Voll, W.; Scheffers, W.; van Dijken, J. Transient-state analysis of metabolic fluxes in
Crabtree-positive and Crabtreenegative yeasts. Appl. Environ. Microbiol. 1990, 56, 281–287. [PubMed]
222. Dalirsani, Z.; Adibpour, M.; Aghazadeh, M.; Amirchaghmaghi, M.; Falaki, F.; Mozafari, P.M.; Hamzei, F.M.
In vitro comparison of inhibitory activity of 10 plant extracts against Candida albicans. Aust. J. Basic Appl. Sci.
2011, 5, 930–935.
223. Junio, H.A.; Sy-Cordero, A.A.; Ettefagh, K.A.; Burns, J.T.; Micko, K.T.; Graf, T.N.; Richter, S.J.; Cannon, R.E.;
Oberlies, N.H.; Cech, N.B. Synergy Directed Fractionation of Botanical Medicines: A Case Study with
Goldenseal (Hydrastis canadensis). J. Nat. Prod. 2011, 74, 1621–1629. [CrossRef] [PubMed]
224. Silva, N.; Fernandes Júnior, A. Biological properties of medicinal plants: A review of their antimicrobial
activity. J. Venom. Anim. Toxins Incl. Trop. Dis. 2010, 16, 402–413. [CrossRef]
225. Martins, N.; Barros, L.; Santos-Buelga, C.; Henriques, M.; Silva, S.; Ferreira, I.C.F.R. Evaluation of bioactive
properties and phenolic compounds in different extracts prepared from Salvia officinalis L. Food Chem. 2015,
170, 378–385. [CrossRef] [PubMed]
226. Dahanukar, S.A.; Kulkarni, R.A.; Rege, N.N. Pharmacology of medicinal plants and natural products.
Indian J. Pharmacol. 2000, 32, S81–S118.
227. Cowan, M. Plant Products as Antimicrobial Agents. Clin. Microbiol. Rev. 1999, 12, 564–582. [PubMed]
228. Sawamura, M. Aroma and functional properties of Japanese yuzu (Citrus junos Tanaka) essential oil.
Aroma Res. 2000, 1, 14–19.
229. Ormancey, X.; Sisalli, S.; Coutiere, P. Formulation of essential oils in functional parfumery. Parfum. Cosmet.
Actual. 2001, 157, 30–40.
230. Sharanappa, R.; Vidyasagar, G. Anti-Candida activity of medicinal plants. A review. Int. J. Pharm. Pharm. Sci.
2013, 5, 9–16.
231. Djilani, A.; Dicko, A. The therapeutic benefits of essential oils. Nutrition, well-being and health. InTech
2012, 155–178.
232. The Chemistry of Aromatherapeutic Oils, 3rd ed.; Bowles, J.E. (Ed.) Griffin Press: Salisbury, Australia, 2003.
233. Gupta, V.; Mittal, P.; Bansal, P.; Khokra, S.L.; Kaushik, D. Pharmacological Potential of Matricaria recutita-A
Review. Int. J. Pharm. Sci. Drug Res. 2010, 2, 12–16.
234. Martín, Á.; Varona, S.; Navarrete, A.; Cocero, M.J. Encapsulation and co-precipitation processes with
supercritical fluids: applications with essential oils. Open Chem. Eng. J. 2010, 4, 31–41. [CrossRef]
235. Dorman, H.; Deans, S. Antimicrobial agents from plants: antibacterial activity of plant volatile oils. J. Appl.
Microbiol. 2000, 88, 308–316. [CrossRef] [PubMed]
236. Aleksic, V.; Knezevic, P. Antimicrobial and antioxidative activity of extracts and essential oils of Myrtus
communis L. Microbiol. Res. 2014, 169, 240–254. [CrossRef] [PubMed]
237. Aidi Wannes, W.; Mhamdi, B.; Sriti, J.; Ben Jemia, M.; Ouchikh, O.; Hamdaoui, G.; Kchouk, M.E.; Marzouk, B.;
Wannes, A. Antioxidant activities of the essential oils and methanol extracts from myrtle (Myrtus communis
var. Italica L.) leaf, stem and flower. Food Chem. Toxicol. 2010, 48, 1362–1370. [CrossRef] [PubMed]
238. Lapornik, B.; Prošek, M.; Wondra, A. Comparison of extracts prepared from plant by-products using different
solvents and extraction time. J. Food Eng. 2005, 71, 214–222. [CrossRef]
239. Pozzatti, P.; Scheid, L.; Spader, T.; Atayde, M.; Santurio, J.; Alves, S. In vitro activity of essential oils extracted
from plants used as spices against fluconazole-resistant and fluconazole-susceptible Candida spp. Canadian.
Can. J. Microbiol. 2008, 54, 950–956. [CrossRef] [PubMed]
J. Fungi 2017, 3, 11 29 of 30
240. Martins, N.; Ferreira, I.C.F.R.; Barros, L.; Carvalho, A.M.; Henriques, M.; Silva, S. Plants used in folk medicine:
The potential of their hydromethanolic extracts against Candida species. Ind. Crops Prod. 2015, 66, 62–67.
[CrossRef]
241. Martins, N.; Ferreira, I.C.F.R.; Henriques, M.; Silva, S. In vitro anti-Candida activity of Glycyrrhiza glabra L.
Ind. Crops Prod. 2016, 83, 81–85. [CrossRef]
242. Prabhakar, K.; Kumar, L.S.; Rajendran, S.; Chandrasekaran, M.; Bhaskar, K.; Sajit Khan, A.K. Antifungal
Activity of Plant Extracts against Candida Species from Oral Lesions. Indian J. Pharm. Sci. 2008, 70, 801–803.
[CrossRef] [PubMed]
243. Estevinho, L.; Afonso, S.; Feás, X. Antifungal effect of lavender honey against Candida albicans, Candida
krusei and Cryptococcus neoformans. J. Food Sci. Technol. 2011, 48, 640–643. [CrossRef] [PubMed]
244. Estevinho, L.; Pereira, A.P.; Moreira, L.; Dias, L.G.; Pereira, E. Antioxidant and antimicrobial effects of
phenolic compounds extracts of Northeast Portugal honey. Food Chem. Toxicol. 2008, 46, 3774–3779.
[CrossRef] [PubMed]
245. Bardy, J.; Nicholas, S.; Kathleen, M.; Alexander, M. A systematic review of honey uses and its potential value
within oncology care. J. Clin. Nurs. 2008, 17, 2604–2623. [CrossRef] [PubMed]
246. Lusby, E.; Coombes, A.; Wilkinson, J. Bactericidal Activity of Different Honeys against Pathogenic Bacteria.
Arch. Med. Res. 2005, 36, 464–467. [CrossRef] [PubMed]
247. Molan, P. Why honey is effective as a medicine. Bee World 2001, 82, 22–40. [CrossRef]
248. Eteraf-Oskouei, T.; Najafi, M. Traditional and Modern Uses of Natural Honey in Human Diseases: A Review.
Iran. J. Basic Med. Sci. 2013, 16, 731–742. [PubMed]
249. Theunissen, F.; Grobler, S.; Gedalia, I. The antifungal action of three South African honeys on Candida albicans.
Apidologie 2001, 32, 371–379. [CrossRef]
250. Irish, J.; Carter, D.; Shokohi, T.; Blair, S. Honey has an antifungal effect against Candida species. Med. Mycol.
2006, 44, 289–291. [CrossRef] [PubMed]
251. Küçük, M.; Kolaylı, S.; Karaog˘lu, S¸.; Ulusoy, E.; Baltacı, C.; Candan, F. Biological activities and chemical
composition of three honeys of different types from Anatolia. Food Chem. 2007, 100, 526–534. [CrossRef]
252. Boukraa, L.; Benbarek, H.; Moussa, A. Synergistic action of starch and honey against Candida albicans in
correlation with diastase number. Brazilian J. Microbiol. 2008, 39, 40–43. [CrossRef]
253. Koc, A.N.; Silici, S.; Ercal, B.D.; Kasap, F.; Hörmet-Öz, H.T.; Mavus-Buldu, H. Antifungal Activity of Turkish
Honey against Candida spp. and Trichosporon spp: An in vitro evaluation. Med. Mycol. 2009, 47, 707–712.
[CrossRef] [PubMed]
254. Quadri, M.; Huraib, S. Manuka honey for central vein catheter exit site care. Semin. Dial. 1999, 12, 396–399.
[CrossRef]
255. Johnson, D.W.; van Eps, C.; Mudge, D.W.; Wiggins, K.J.; Armstrong, K.; Hawley, C.M.; Campbell, S.B.;
Isbel, N.M.; Nimmo, G.R.; Gibbs, H. Randomized, controlled trial of topical exit-site application of honey
(medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients.
J. Am. Soc. Nephrol. 2005, 16, 1456–1462. [CrossRef] [PubMed]
256. Freire, F.; Ferraresi, C.; Jorge, A.O.C.; Hamblin, M.R. Photodynamic therapy of oral Candida infection in a
mouse model. J. Photochem. Photobiol. B Biol. 2016, 159, 161–168. [CrossRef] [PubMed]
257. de Oliveira Mima, E.G.; Pavarina, A.C.; Dovigo, L.N.; Vergani, C.E.; de Souza Costa, C.A.; Kurachi, C.;
Bagnato, V.S. Susceptibility of Candida albicans to photodynamic therapy in a murine model of oral candidosis.
Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 109, 392–401. [CrossRef] [PubMed]
258. de Souza, S.C.; Junqueira, J.C.; Balducci, I.; Koga-Ito, C.Y.; Munin, E.; Jorge, A.O.C. Photosensitization of
different Candida species by low power laser light. J. Photochem. Photobiol. B Biol. 2006, 83, 34–38. [CrossRef]
[PubMed]
259. Souza, R.C.; Junqueira, J.C.; Rossoni, R.D.; Pereira, C.A.; Munin, E.; Jorge, A.O.C. Comparison of the
photodynamic fungicidal efficacy of methylene blue, toluidine blue, malachite green and low-power laser
irradiation alone against Candida albicans. Lasers Med. Sci. 2010, 25, 385–389. [CrossRef] [PubMed]
260. Martinez, L.R.; Nimrichter, L.; Nosanchuk, J.D.; Baltazar, L.M.; Ray, A.; Santos, D.A.; Cisalpino, P.S.;
Friedman, A.J. Antimicrobial photodynamic therapy: an effective alternative approach to control fungal
infections. Front. Microbiol. 2015, 6, 202.
J. Fungi 2017, 3, 11 30 of 30
261. Giroldo, L.M.; Felipe, M.P.; de Oliveira, M.A.; Munin, E.; Alves, L.P.; Costa, M.S. Photodynamic antimicrobial
chemotherapy (PACT) with methylene blue increases membrane permeability in Candida albicans.
Lasers Med. Sci. 2009, 24, 109–112. [CrossRef] [PubMed]
262. Dovigo, L.N.; Pavarina, A.C.; de Oliveira Mima, E.G.; Giampaolo, E.T.; Vergani, C.E.; Bagnato, V.S. Fungicidal
effect of photodynamic therapy against fluconazole-resistant Candida albicans and Candida glabrata. Mycoses
2011, 54, 123–130. [CrossRef] [PubMed]
263. Vartak, A.; Mutalik, V.; Parab, R.R.; Shanbhag, P.; Bhave, S.; Mishra, P.D.; Mahajan, G.B. Isolation of a new
broad spectrum antifungal polyene from Streptomyces sp. MTCC 5680. Lett. Appl. Microbiol. 2014, 58,
591–596. [CrossRef] [PubMed]
264. de Souza, T.B.; de Oliveira Brito, K.M.; Silva, N.C.; Rocha, R.P.; de Sousa, G.F.; Duarte, L.P.; Coelho, L.F.L.;
Dias, A.L.T.; Veloso, M.P.; Carvalho, D.T.; et al. New eugenol glucoside-based derivative shows fungistatic
and fungicidal activity against opportunistic Candida glabrata. Chem. Biol. Drug Des. 2015, 87, 83–89.
[CrossRef] [PubMed]
265. Casanova, B.B.; Muniz, M.N.; Oliveira, T.; Oliveira, L.F.; Machado, M.M.; Fuentefria, A.M.; Gosmann, G.;
Gnoatto, S.C.B. Synthesis and biological evaluation of some hydrazone derivatives as anti-inflammatory
agents. Lett. Drug Des. Discov. 2012, 9, 310–315.
266. Ferreira, B.D.S.; de Almeida, A.M.; Nascimento, T.C.; de Castro, P.P.; Silva, V.L.; Diniz, C.G.; Le Hyaric, M.
Synthesis and biological evaluation of a new series of N-acyldiamines as potential antibacterial and antifungal
agents. Bioorg. Med. Chem. Lett. 2014, 24, 4626–4629. [CrossRef] [PubMed]
267. Abrão, P.H.O.; Pizi, R.B.; de Souza, T.B.; Silva, N.C.; Fregnan, A.M.; Silva, F.N.; Coelho, L.F.L.;
Malaquias, L.C.C.; Dias, A.L.T.; Dias, D.F.; Veloso, M.P.; Carvalho, D.T. Synthesis and biological evaluation
of new eugenol mannich bases as promising antifungal agents. Chem. Biol. Drug Des. 2015, 86, 459–465.
[CrossRef] [PubMed]
268. Raman, N.; Lee, M.-R.; Lynn, D.; Palecek, S. Antifungal Activity of 14-Helical β-peptides against planktonic
cells and biofilms of Candida species. Pharmaceuticals 2015, 8, 483–503. [CrossRef] [PubMed]
269. Silva-Dias, A.; Miranda, I.M.; Branco, J.; Cobrado, L.; Monteiro-Soares, M.; Pina-Vaz, C.; Rodrigues, A.G.
In vitro antifungal activity and in vivo antibiofilm activity of cerium nitrate against Candida species.
J. Antimicrob. Chemother. 2014, 70, 1083–1093. [CrossRef] [PubMed]
270. Joseph, M.R.P.; Al-Hakami, A.M.; Assiry, M.M.; Jamil, A.S.; Assiry, A. M.; Shaker, M.A.; Hamid, M.E. In vitro
anti-yeast activity of chloramphenicol: A preliminary report. J. Med. Mycol. 2015, 25, 17–22. [CrossRef] [PubMed]
271. Ning, Y.; Ling, J.; Wu, C.D. Synergistic effects of tea catechin epigallocatechin gallate and antimycotics
against oral Candida species. Arch. Oral Biol. 2015, 60, 1565–1570. [CrossRef] [PubMed]
272. Perera, J.; Weerasekera, M.; Kottegoda, N. Slow release anti-fungal skin formulations based on citric acid
intercalated layered double hydroxides nanohybrids. Chem. Cent. J. 2015, 9, 27. [CrossRef] [PubMed]
273. Silva, S.; Pires, P.; Monteiro, D.R.; Negri, M.; Gorup, L.F.; Camargo, E.R.; Barbosa, D.B.; Oliveira, R.;
Williams, D.W.; Henriques, M.; Azeredo, J. The effect of silver nanoparticles and nystatin on mixed biofilms
of Candida glabrata and Candida albicans on acrylic. Med. Mycol. 2013, 51, 178–184. [CrossRef] [PubMed]
274. Casella, T.M.; Eparvier, V.; Mandavid, H.; Bendelac, A.; Odonne, G.; Dayan, L.; Duplais, C.; Espindola, L.S.;
Stien, D. Antimicrobial and cytotoxic secondary metabolites from tropical leaf endophytes: Isolation of
antibacterial agent pyrrocidine C from Lewia infectoria SNB-GTC2402. Phytochemistry 2013, 96, 370–377.
[CrossRef] [PubMed]
275. Nirma, C.; Eparvier, V.; Stien, D. Antifungal Agents from Pseudallescheria boydii SNB-CN73 Isolated from a
Nasutitermes sp. Termite. J. Nat. Prod. 2013, 76, 988–991. [CrossRef] [PubMed]
276. Nirma, C.; Eparvier, V.; Stien, D. Antibacterial ilicicolinic acids c and d and ilicicolinal from
neonectria discophora SNB-CN63 isolated from a termite nest. J. Nat. Prod. 2015, 78, 159–162. [CrossRef]
[PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
